1. Procedure Overview

This category encompasses important cardiac and thoracic surgical procedures that, while less common than coronary artery bypass grafting or valve surgery, are critical for treating specific, often complex, heart and lung conditions. These procedures address structural abnormalities, advanced heart failure, certain cardiac tumours, and specialised circulatory problems that cannot be managed with medication alone.

The primary procedures in this category include pericardiectomy (surgical removal of the pericardium, often for constrictive pericarditis), pericardial window (creating an opening to drain fluid around the heart), cardiac tumour resection (removal of tumours such as atrial myxoma), left ventricular assist device (LVAD) implantation (mechanical pump for severe heart failure), heart transplantation (replacing a failing heart with a donor heart), pulmonary thromboendarterectomy (removing chronic blood clots from pulmonary arteries), and surgical ventricular restoration (reconstructing the left ventricle after heart attack).

These procedures are performed in specialised cardiac surgery centres with expertise in complex cardiac surgery. Many patients travel internationally to access high-volume centres with superior outcomes for these less common operations. Medical tourism destinations such as India, Turkey, Thailand, and Singapore offer these procedures at significantly lower costs than Western countries, often with equally qualified surgeons and modern facilities.

2. Key Facts at a Glance

Aspect	Details
Also known as	Specialised cardiac procedures, advanced heart surgery, thoracic procedures
Procedure type	Category encompassing various open-heart and thoracic surgeries
Typical duration	Varies widely: 2-12 hours depending on specific procedure
Anaesthesia	General anaesthesia for all procedures in this category
Hospital stay	3-21 days depending on procedure (pericardial window: 3-5 days; heart transplant: 14-21 days)
Initial recovery	2-8 weeks for basic recovery, varies by procedure
Full recovery	3-12 months depending on procedure complexity
Longevity	Varies: pericardiectomy often curative; LVAD may last 2-5 years; heart transplant 10+ years with proper care
Common in this category	Pericardiectomy, pericardial window, cardiac tumour resection, LVAD, heart transplant, PTE, SVR

Note: This table represents a category of diverse procedures. Specific details vary considerably between procedures.

3. Anatomy and How the Heart Condition Develops

The Pericardium:

The pericardium is a thin, sac-like membrane that surrounds the heart, consisting of two layers with a small amount of fluid between them. This fluid allows the heart to move smoothly within the sac. When the pericardium becomes chronically inflamed (often from viral infections, tuberculosis, or after cardiac surgery), it can thicken and calcify, restricting the heart’s ability to fill properly — a condition called constrictive pericarditis. Similarly, excess fluid can accumulate in the pericardial space (pericardial effusion), compressing the heart and impairing function (cardiac tamponade).

Cardiac Tumours:

Primary cardiac tumours are rare, with atrial myxoma being the most common benign type (75% of primary cardiac tumours). These gelatinous tumours typically arise from the atrial septum and can grow large enough to obstruct blood flow or cause emboli (break off and travel to brain or other organs). While usually benign, they require surgical removal due to their potential to cause stroke, heart failure, or sudden death.

Advanced Heart Failure:

When the heart muscle becomes severely weakened (ejection fraction <25-30%) from various causes (coronary artery disease, viral myocarditis, genetic cardiomyopathy), medications alone may be insufficient. The heart dilates and changes shape, becoming less efficient. For these patients, mechanical circulatory support (LVAD) or heart replacement (transplantation) may be necessary.

Pulmonary Hypertension and Chronic Thromboembolic Disease:

Blood clots that fail to dissolve after pulmonary embolism can organise into scar tissue in the pulmonary arteries, causing chronic thromboembolic pulmonary hypertension (CTEPH). This places enormous strain on the right heart, causing right heart failure. Pulmonary thromboendarterectomy (PTE) surgically removes this organised clot material.

Ventricular Remodelling After Heart Attack:

After a large heart attack (myocardial infarction), the damaged area of the left ventricle thins and bulges outward, forming an aneurysm. This changes the heart’s shape and reduces pumping efficiency. Surgical ventricular restoration (SVR) removes this non-functioning area and reconstructs the ventricle to a more normal size and shape.

4. Conditions Treated

This category of procedures treats diverse cardiac and thoracic conditions:

Pericardial Conditions:

Constrictive pericarditis — thickened, adherent pericardium restricting heart filling
Recurrent pericardial effusion — repeated fluid accumulation around the heart
Cardiac tamponade — life-threatening compression of the heart by fluid
Effusive-constrictive pericarditis — combination of fluid and constriction

Cardiac Tumours:

Atrial myxoma — most common benign cardiac tumour
Other benign tumours — papillary fibroelastoma, lipoma, fibroma
Malignant cardiac tumours — sarcoma (rare, requires specialised treatment)

Advanced Heart Failure:

End-stage heart failure — severe symptoms despite maximal medical therapy
Ischaemic cardiomyopathy — weakened heart muscle from coronary disease
Dilated cardiomyopathy — enlarged, weakened heart from various causes
Bridge to transplant — LVAD as temporary support while awaiting donor heart
Destination therapy — permanent LVAD for patients not eligible for transplant

Pulmonary Vascular Disease:

Chronic thromboembolic pulmonary hypertension (CTEPH) — organised blood clots in pulmonary arteries causing pulmonary hypertension
Surgically accessible chronic thromboembolic disease

Post-Heart Attack Complications:

Left ventricular aneurysm — bulging, scarred area after heart attack
Ischaemic cardiomyopathy with ventricular remodelling — abnormal heart shape and size after myocardial infarction

5. Symptoms and Warning Signs

Symptoms vary by condition but often include:

Pericardial Disease Symptoms:

Progressive shortness of breath — worsening over months, initially with exertion, eventually at rest
Abdominal swelling and distension — fluid accumulation in liver and gut (constrictive pericarditis)
Leg swelling (edema) — fluid retention from elevated venous pressure
Fatigue and weakness — reduced cardiac output
Jugular venous distension — prominent neck veins
Pericardial knock — early heart sound heard by doctor

Cardiac Tamponade (Emergency):

Sudden severe shortness of breath
Cold, clammy skin — signs of shock
Low blood pressure
Rapid, weak pulse
Muffled heart sounds — fluid dampens sound

Cardiac Tumour Symptoms:

Symptoms of heart failure — shortness of breath, swelling, fatigue
Palpitations or irregular heartbeats — tumour interfering with electrical system
Stroke-like symptoms — if tumour fragments travel to brain (confusion, weakness, speech difficulty)
Constitutional symptoms — weight loss, fever, malaise (malignant tumours)
Heart murmur — from tumour interfering with valve function

Advanced Heart Failure Symptoms:

Severe shortness of breath — at rest, with minimal activity, or when lying flat
Extreme fatigue — unable to perform normal activities
Swelling — legs, abdomen, entire body (anasarca)
Loss of appetite and nausea — poor gut perfusion
Difficulty concentrating — poor brain blood flow
Chest pain or pressure — from heart strain

CTEPH Symptoms:

Progressively worsening shortness of breath — over months to years
Chest pain — right heart strain
Light-headedness or fainting — low cardiac output
Swelling — legs, abdomen (right heart failure)
Blue lips or skin (cyanosis) — low oxygen levels

6. When Is This Procedure Recommended?

Specialist cardiac surgeons and cardiologists recommend these procedures based on established guidelines from the American College of Cardiology/American Heart Association (ACC/AHA), European Society of Cardiology (ESC), and other professional societies:

Pericardiectomy Indications:

Symptomatic constrictive pericarditis confirmed by echocardiography, CT, or cardiac MRI
Significant fluid retention despite diuretic therapy
Progressive symptoms affecting quality of life
Liver or kidney dysfunction from venous congestion
Failure of medical management — symptoms persisting for 3-6 months despite optimal therapy

Pericardial Window Indications:

Recurrent pericardial effusion requiring repeated drainage procedures
Malignant effusion — cancer causing fluid accumulation
Suspected bacterial pericarditis — for drainage and diagnosis
Cardiac tamponade — emergency life-saving procedure
High-risk for tamponade — large effusion with signs of compression

Cardiac Tumour Resection Indications:

Symptomatic atrial myxoma — causing obstruction, emboli, or constitutional symptoms
Any cardiac tumour — most cardiac tumours should be removed due to risk of embolization or obstruction
Large tumours (>5cm) even if asymptomatic (high risk of complications)
Malignant tumours — when complete resection possible

LVAD Indications:

End-stage heart failure (Stage D) — New York Heart Association Class IV symptoms despite optimal medical therapy
Ejection fraction <25% — severely reduced heart pumping function
Bridge to transplant — while awaiting donor heart (often 6-12 months wait)
Destination therapy — permanent support for patients not eligible for transplant (age, comorbidities)
Bridge to recovery — temporary support for potentially reversible heart failure (myocarditis, post-cardiotomy shock)

Heart Transplant Indications:

End-stage heart failure refractory to all other treatments
Severe symptomatic heart failure — repeated hospitalisations, poor quality of life
Peak oxygen consumption <14 ml/kg/min — severely limited exercise capacity
Need for inotropes — requiring continuous intravenous heart-strengthening medications
Recurrent life-threatening arrhythmias uncontrolled by medications/devices
No contraindications to transplant — suitable age (<65-70 typically), no active infection, no severe irreversible other organ disease

PTE Indications:

Chronic thromboembolic pulmonary hypertension (CTEPH) confirmed by specialised imaging
Surgically accessible disease — clot material in main pulmonary arteries (not too distal)
New York Heart Association Class II-IV — symptomatic despite medical therapy
Pulmonary vascular resistance <1000 Wood units — operable range (higher risk above this)

Surgical Ventricular Restoration Indications:

Large left ventricular aneurysm after heart attack
Heart failure symptoms despite optimal medical therapy and revascularization
Viable myocardium in non-aneurysmal areas (confirmed by PET or MRI)
Coronary artery disease amenable to concurrent CABG (usually required)

7. Who Is a Suitable Candidate?

Suitability varies by specific procedure, but general principles include:

For Pericardiectomy:

Confirmed constrictive pericarditis with characteristic imaging findings
Symptomatic with good quality of life potential after surgery
Adequate overall health to tolerate major surgery
Reasonable life expectancy (>1-2 years) from non-cardiac causes
No severe pulmonary hypertension — pericardiectomy less effective if pulmonary hypertension is severe and permanent

For Pericardial Window:

Recurrent symptomatic effusion
Life expectancy >3 months (for malignant effusions)
Adequate platelet count and coagulation — high bleeding risk during procedure

For Cardiac Tumour Resection:

Resectable tumour — technically removable with acceptable risk
No metastatic disease (for malignant tumours)
Adequate heart function to tolerate surgery

For LVAD:

End-stage heart failure meeting guideline criteria
Adequate end-organ function — kidneys, liver, lungs not severely damaged
Psychological stability — able to manage device and follow-up
Social support — help at home for device management
No active infection — LVAD infection risk significant
No severe neurological injury from previous strokes

For Heart Transplant:

Age <65-70 (some centres extend to 72 with careful selection)
No active cancer — cancer-free typically 3-5 years
No severe irreversible other organ disease — liver failure, severe lung disease
No active infection
Adequate social support — help with medications and follow-up
Psychological stability — able to adhere to complex medication regimen
No severe obesity — BMI typically <35-40
Able to afford immunosuppressant medications (or insurance coverage)

For PTE:

CTEPH with surgically accessible disease
Symptomatic despite optimal medical therapy
Acceptable surgical risk — generally younger patients, reasonable right heart function
Motivated to undergo major surgery with prolonged recovery

For SVR:

Large anterior aneurysm after heart attack
Heart failure symptoms despite optimal therapy and CABG
Viable myocardium in other territories
Coronary anatomy suitable for concurrent CABG

8. Who May Not Be Suitable?

Certain conditions increase risk or preclude these procedures:

Pericardiectomy Contraindications:

Severe, permanent pulmonary hypertension — pericardiectomy may not improve symptoms and carries high risk
Very advanced frailty — limited life expectancy (<6-12 months)
Active infection or sepsis
Severe coagulopathy — inability to clot blood normally

Cardiac Tumour Contraindications:

Metastatic disease — tumour spread to other organs (for malignant tumours)
Tumour invading critical structures — unresectable location
Very poor heart function — unable to tolerate surgery

LVAD Contraindications:

Severe right heart failure — LVAD may worsen right heart function
Severe pulmonary hypertension — irreversible high lung pressures
Active infection — LVAD would become infected
Severe neurological injury — poor quality of life after device
Lack of social support — unable to manage device at home
End-stage kidney or liver failure — limited benefit
Very poor nutritional status — albumin <2.5-3.0 g/dL
Severe vascular disease — inability to place device

Heart Transplant Contraindications:

Active cancer — most recent cancers require 3-5 years cancer-free period
Severe irreversible other organ disease — liver failure, severe lung disease (COPD)
Active infection — must be treated before transplant
Severe obesity — BMI >35-40 (weight loss required)
Older age — >70-75 (some flexibility with excellent health)
Severe psychiatric illness — unable to adhere to medication regimen
Lack of social support — no help for medications and follow-up
Substance abuse — active alcohol/drug use
Fixed high pulmonary vascular resistance — >4-5 Wood units (donor heart would fail)
Severe diabetes with complications — organ damage

PTE Contraindications:

Distal disease only — clot material too far into lung periphery to access surgically
Severe right heart failure — very high surgical risk
Significant comorbidities — severe lung, liver, or kidney disease
Very advanced age — >75-80 (individual assessment)

SVR Contraindications:

No viable myocardium — entire heart scarred, no benefit from reconstruction
Severe mitral regurgitation — may need different approach
Very poor heart function — ejection fraction <15-20%
Advanced heart failure — may need transplant or LVAD instead

9. Types and Techniques of the Procedure

This category encompasses diverse procedures with varied approaches:

Pericardiectomy Approaches:

Complete pericardiectomy — radical removal of most or all pericardium (best outcomes, more complex)
Anterior pericardiectomy — removal of pericardium over ventricles (simpler, may be incomplete)
Phrenic nerve preservation — careful dissection to preserve phrenic nerves (diaphragm function)
Thoracoscopic pericardiectomy — minimally invasive approach with camera and instruments (select cases)

Pericardial Window Techniques:

Surgical subxiphoid window — incision below breastbone, create opening in pericardium
Thoracoscopic window — minimally invasive with camera (smaller incisions)
Pleural drainage — window directs fluid into pleural space where it’s absorbed
Peritoneal drainage — window directs fluid into abdominal cavity

Cardiac Tumour Resection:

Complete tumour excision — removal of entire tumour with margin of normal tissue
Atrial septal reconstruction — repair of septum after myxoma removal (patch closure)
Valve-sparing techniques — preserve valve function when possible
Minimally invasive approaches — small incisions for selected tumours

LVAD Types:

Implantable continuous-flow LVADs — modern devices (HeartMate 3, HeartWare HVAD)
Pulsatile devices — older technology (rarely used now)
Bridge-to-transplant devices — smaller, designed for temporary support
Destination therapy devices — durable, long-term support

Heart Transplant Techniques:

Orthotopic heart transplantation — removal of recipient heart, placement of donor heart in same location
Bicaval anastomosis technique — donor heart connected to both vena cavae (reduces tricuspid regurgitation)
Standard technique — donor atria connected to recipient atria
Heterotopic transplantation — donor heart placed alongside failing heart (rare, “piggyback” transplant)

PTE Techniques:

Cardiopulmonary bypass with deep hypothermic arrest — cooled to 18-20°C, circulation stopped
True endarterectomy — complete removal of organised clot material and inner lining of pulmonary arteries
Bilateral approach — both left and right pulmonary arteries cleared
Careful dissection — in actual plane of adventitia (outer layer) to ensure complete removal

SVR Approaches:

Endoventricular circular patch plasty (Dor procedure) — removal of aneurysm, patch closure of ventricle
Linear repair — simpler closure of aneurysm
Coronary artery bypass — almost always combined with CABG
Valve procedures — may add mitral valve repair if regurgitation present

10. Traditional, Minimally Invasive and Advanced Approaches

Traditional Open Surgical Approaches:

Most procedures in this category use traditional sternotomy (breastbone incision) or thoracotomy (side chest incision) for optimal access. These provide excellent exposure, allow precise surgery, and remain the standard of care for complex cases.

Advantages: Complete access, proven long-term results, ability to address multiple issues simultaneously. Disadvantages: Larger incisions, longer recovery, more pain, temporary activity restrictions.

Minimally Invasive and Thoracoscopic Techniques:

Thoracoscopic pericardiectomy and pericardial window use small incisions (3-5 ports) with camera-guided instruments. Suitable for select patients without extensive pericardial calcification or adhesions.

Advantages: Smaller incisions, less pain, faster recovery, shorter hospital stay. Disadvantages: Limited to less complex cases, technically demanding, not suitable for all patients.

Robotic-Assisted Approaches:

Emerging technology for select cardiac tumour resections and some pericardial procedures. Offers enhanced visualization and instrument dexterity.

Advantages: 3D high-definition vision, precise instruments, small incisions. Disadvantages: Limited availability, high cost, longer operative time, limited to suitable cases.

Hybrid and Combined Procedures:

SVR almost always combined with CABG — address both the aneurysm and the underlying coronary disease. Some patients also require mitral valve repair for ischemic mitral regurgitation.

Heart transplant with LVAD explantation — patients with previous LVADs undergo transplant after donor heart available.

LVAD with concomitant procedures — some LVAD patients require simultaneous aortic valve repair, tricuspid valve repair, or arrhythmia surgery (maze procedure for atrial fibrillation).

Advanced Circulatory Support:

Total artificial heart — for biventricular failure (both sides of heart failing). More complex than LVAD, serves as bridge to transplant in select cases.

ECMO (extracorporeal membrane oxygenation) — temporary heart-lung bypass for critically ill patients (bridge to decision, bridge to recovery, or bridge to LVAD/transplant).

The choice of approach depends on the specific procedure, patient anatomy, surgeon expertise, and available technology. Traditional open surgery remains most common for these complex operations.

11. Procedure vs Alternative Treatments

Pericardiectomy vs Medical Management:

Medical management for constrictive pericarditis includes diuretics for fluid removal, anti-inflammatory medications, and careful monitoring. However, medical therapy does not reverse pericardial thickening and only manages symptoms. Pericardiectomy is potentially curative, removing the constriction and allowing normal heart filling. For symptomatic patients, pericardiectomy offers definitive treatment whereas medical management is temporary.

Pericardial Window vs Repeated Pericardiocentesis:

Pericardiocentesis (needle drainage of pericardial fluid) provides immediate relief for tamponade or large effusions. However, fluid often reaccumulates, requiring repeated procedures. Pericardial window creates a permanent drainage pathway, preventing recurrence. For recurrent effusions, window is superior to repeated needle drainage.

Cardiac Tumour Resection vs Medical Management/Embolization:

Cardiac tumours almost always require surgical removal because they carry high risk of embolization (travelling to brain or organs causing stroke) and obstruction. Medical therapy only addresses symptoms. Embolization (blocking tumour blood supply) is rarely effective and often makes subsequent surgery more difficult. Surgical resection is definitive treatment.

LVAD vs Medical Management for Heart Failure:

Maximal medical therapy for heart failure includes ACE inhibitors, beta-blockers, aldosterone antagonists, diuretics, and devices (ICD, CRT). For end-stage heart failure, even maximal medical therapy cannot sustain life indefinitely. LVAD provides mechanical circulatory support, dramatically improving survival and quality of life for patients who would otherwise die from heart failure. LVAD is life-saving compared to medical therapy alone.

Heart Transplant vs LVAD Destination Therapy:

Transplant offers the best quality of life and longest survival (10+ years average) for eligible patients. LVAD destination therapy provides alternative for patients not eligible for transplant (age, comorbidities) or who decline transplant. Transplant requires immunosuppression and carries rejection risk; LVAD requires device management and carries stroke/infection risk. For suitable candidates, transplant generally superior.

PTE vs Medical Management for CTEPH:

Medical therapy for pulmonary hypertension (vasodilators, diuretics) does not treat the organised clot in CTEPH. PTE is potentially curative, removing the obstruction and normalising pulmonary pressures in many patients. For eligible patients, PTE offers dramatic improvement versus palliative medical therapy.

SVR vs Medical Management/Transplant:

Medical therapy for ischemic cardiomyopathy and ventricular aneurysm includes standard heart failure medications. SVR reconstructs the ventricle to more normal size and shape, potentially improving function. For patients with large aneurysms and viable myocardium, SVR combined with CABG may provide superior outcomes to medical therapy alone, though transplant may be better for very advanced disease.

12. Diagnosis and Pre-Procedure Evaluation

Accurate diagnosis and thorough evaluation are essential before these complex procedures:

Initial Assessment:

Comprehensive medical history focusing on symptom progression, previous cardiac treatments, and comorbid conditions
Physical examination including detailed heart examination, assessment of fluid overload, and overall functional status
Review of all previous cardiac tests and interventions
Assessment of exercise capacity and quality of life

Cardiac Testing:

For Pericardial Disease:

Echocardiogram — shows pericardial thickening, septal bounce (diagnostic of constriction), respiratory variation in valve flow patterns
CT scan — shows pericardial calcification (especially helpful for surgical planning)
Cardiac MRI — best test for pericardial thickening and inflammation, shows septal bounce and tissue characterisation
Cardiac catheterisation — shows equalisation of diastolic pressures (ventricular pressure equalisation), dip-and-plateau pattern

For Cardiac Tumours:

Echocardiogram (TTE and TEE) — locates tumour, size, attachment point, effect on valves
CT scan — detailed anatomy, relationship to other structures
Cardiac MRI — tissue characterisation, distinguishing tumour types
Coronary angiography — shows tumour blood supply (important for surgical planning)

For Heart Failure/LVAD/Transplant Evaluation:

Echocardiogram — heart size, function, valve function, ejection fraction, pulmonary pressures
Right heart catheterisation — pulmonary vascular resistance (crucial for transplant eligibility)
Cardiac MRI — heart function, scar tissue, viability
Stress test — exercise capacity, peak oxygen consumption
Coronary angiography — coronary anatomy (need for concurrent CABG)

For CTEPH/PTE Evaluation:

CT pulmonary angiography — shows organised thrombi in main pulmonary arteries
V/Q scan — mismatched perfusion defects (suggests CTEPH)
Right heart catheterisation — pulmonary pressures, pulmonary vascular resistance
Conventional pulmonary angiography — detailed roadmap of clot location and extent
Pulmonary function tests — assess lung disease

For SVR Evaluation:

Echocardiogram — ventricular size, aneurysm size, valve function
Left ventriculography — shape and size of ventricle, aneurysm extent
Cardiac MRI — scar tissue, viable myocardium, ventricular volumes
Stress test — viability of non-aneurysmal myocardium

Additional Testing:

Laboratory tests — blood count, kidney/liver function, electrolytes, cholesterol, diabetes markers
Pulmonary function tests — lung function (especially for thoracotomy approaches or PTE)
Carotid ultrasound — stroke risk assessment
Abdominal ultrasound — liver assessment (especially for heart failure patients)
Psychological evaluation — especially for LVAD and transplant candidates
Social work assessment — support system, financial considerations

13. Tests Required Before the Procedure

Once decision for surgery is made, additional testing assesses surgical fitness:

Blood Tests:

Complete blood count (CBC) — anemia, infection, platelet count
Comprehensive metabolic panel — kidney function, liver function, electrolytes
Coagulation studies (PT/INR, PTT) — bleeding/clotting ability
Cardiac biomarkers (troponin, BNP) — heart muscle damage, heart failure severity
HbA1c — diabetes control assessment
Lipid profile — cholesterol levels
Thyroid function tests — thyroid disorders affect heart function
Inflammatory markers (CRP, ESR) — especially for pericardial disease

Imaging:

Chest X-ray — heart size, lung condition, aortic calcification
Coronary angiogram — if not recently performed, repeated for surgical planning
Carotid ultrasound — stroke risk assessment
Abdominal ultrasound — liver assessment, ascites

Specialised Testing:

Pulmonary function tests — lung capacity, especially for patients with lung disease or prior to PTE
Doppler ultrasound of leg veins — assess saphenous vein suitability (if grafts needed)
Quantitative perfusion scan — for PTE candidates (pulmonary blood flow distribution)

Additional Assessments:

Anesthesia evaluation — airway assessment, medication review, risk stratification
Dental evaluation — source of infection clearance (especially for transplant/LVAD)
Psychological evaluation — coping ability, mental health (especially for LVAD/transplant)
Social work assessment — support system, financial planning, post-discharge needs
Financial counselling — cost estimation, insurance coverage (especially for LVAD/transplant)

Transplant-Specific Testing:

Tissue typing (HLA typing) — for donor matching
Panel Reactive Antibodies (PRA) — sensitisation to previous transplants or transfusions
Crossmatch testing — when donor available
Infectious disease screening — HIV, hepatitis, CMV, EBV, tuberculosis
Cancer screening — age-appropriate screening (mammogram, colonoscopy, PSA)
Age-specific testing — prostate exam, mammogram, colonoscopy as indicated

Preoperative Screening:

Blood type and crossmatch — for potential transfusion
Infection screening (MRSA, etc.)
Pregnancy test in women of childbearing age
Urinalysis — infection, kidney function

Results reviewed to optimize patient condition before surgery. May require medication adjustments, additional treatments, or further specialist consultations. For transplant patients, listing process includes comprehensive evaluation and approval by transplant committee.

14. How to Prepare for the Procedure

1-2 Weeks Before Surgery:

Attend preoperative education class if offered (especially important for LVAD/transplant patients)
Arrange post-surgery support (family caregiving, help at home) — crucial for LVAD patients
Complete legal documents (healthcare proxy, living will, power of attorney)
Discontinue certain medications as directed (aspirin, blood thinners, NSAIDs, herbal supplements) — timing varies by procedure and surgeon
Optimise chronic conditions (diabetes, hypertension, COPD, heart failure)
For transplant patients: arrange housing near transplant centre for post-transplant monitoring (typically 2-3 months nearby)
For LVAD patients: identify primary caregiver who will receive device training

1 Week Before:

Prepare home for recovery (sleeping arrangements, remove fall hazards, bathroom safety)
Pack hospital bag (loose clothing, toiletries, phone charger, reading materials, pillows for splinting cough)
Arrange transportation home from hospital
Plan who will update family/friends during surgery
For LVAD/transplant: ensure pharmacy arranged for complex postoperative medications
For transplant: arrange accommodation near centre

Day Before Surgery:

Follow fasting instructions typically starting midnight (no food or drink)
Shower with antibacterial soap as instructed
Sleep well, manage anxiety (normal to be nervous)
Follow medication instructions — some drugs taken, others withheld
For transplant/LVAD: final preoperative coordination with transplant team

Day of Surgery:

Arrive at hospital at scheduled time
Remove jewelry, glasses, contacts, nail polish, makeup
Change into hospital gown
Meet surgical team and confirm procedure details
IV line placed for medications and fluids
Premedication given to reduce anxiety
Family shown waiting area and given timeline
For transplant: remain ready to come to hospital immediately when donor available

Transplant-Specific Preparation:

Keep transplant pager/cell phone on at all times
Arrange rapid transportation to hospital
Have bag packed and ready
Know contact numbers for transplant coordinator
Maintain optimal health — avoid infections, report illnesses promptly
Stay within reasonable distance (typically 2-4 hours travel time) of transplant centre

LVAD-Specific Preparation:

Identify and train primary caregivers — usually 2-3 people who will receive extensive device management training
Prepare home environment — ensure adequate electrical supply, plan for device equipment
Arrange home nursing if needed initially
Understand driving restrictions (often cannot drive with LVAD)

15. Procedure: Step-by-Step

Procedures vary significantly; representative steps for major categories:

Pericardiectomy Steps:

General anesthesia induced; breathing tube placed
Monitoring lines inserted (arterial line, central venous line, urinary catheter)
Sternum divided (sternotomy) or thoracotomy incision made
Pericardium exposed — often thickened, adherent to heart
Careful dissection begun — pericardium peeled from heart surface
Phrenic nerves identified and carefully preserved
Pericardium removed from anterior and diaphragmatic surfaces of heart
Posterior pericardium may be left or removed depending on extent of disease
Hemostasis achieved — meticulous control of bleeding
Chest drains placed
Sternum wired or thoracotomy closed
Patient transferred to ICU

Pericardial Window Steps:

General or local anesthesia with sedation
Small incision below breastbone (subxiphoid approach)
Pericardium identified
Opening created in pericardium (window)
Fluid drained
Edge of pericardium sutured to skin or pleural surface (creates permanent drainage path)
Drain placed
Incision closed

Cardiac Tumour Resection (e.g., Atrial Myxoma) Steps:

General anesthesia; standard cardiac surgery preparation
Sternotomy; heart-lung machine established
Right atrium opened
Tumour identified, usually attached to atrial septum
Tumour carefully removed with surrounding tissue margin
Atrial septal defect repaired (patch closure usually needed)
Heart restarted; patient weaned from bypass
Chest closed with drains

LVAD Implantation Steps:

General anesthesia; cardiac surgery preparation
Sternotomy; heart-lung machine established
Inflow cannula placed in left ventricle apex (pumping chamber)
Outflow cannula connected to aorta
Device placed in abdomen (below diaphragm) or upper abdomen
All connections made and tested
Device started; heart function and device function assessed
Drains placed; chest closed
Device external components connected and programmed

Heart Transplantation Steps:

General anesthesia; complete cardiac surgery preparation
Sternotomy; heart-lung machine established
Recipient heart removed (careful dissection of all connections)
Donor heart implanted (anastomoses to aorta, pulmonary artery, left atrium, right atrium)
Heart restarted; reperfusion began
Hemostasis achieved
Temporary pacing wires placed
Chest closed with drains
Immunosuppressant medications started

Pulmonary Thromboendarterectomy (PTE) Steps:

General anesthesia; cardiac surgery preparation
Sternotomy; heart-lung machine established
Patient cooled deeply (18-20°C) — circulatory arrest needed
Main pulmonary arteries opened
True endarterectomy performed — organised clot material and inner lining dissected free and removed
Continue into smaller branches bilaterally until normal vessel reached
Pulmonary arteries closed
Patient rewarmed; heart restarted
Chest closed with drains

Surgical Ventricular Restoration (SVR) Steps:

General anesthesia; cardiac surgery preparation
Sternotomy; heart-lung machine established
Aneurysm area of left ventricle opened
Thrombus (clot) removed from ventricle
Aneurysmal tissue resected
Ventricle reconstructed — often with patch (Dor procedure)
Concurrent CABG performed (almost always)
May add mitral valve repair if regurgitation present
Heart restarted; chest closed

Typical Procedure Duration:

Pericardiectomy: 3-5 hours
Pericardial window: 1-2 hours
Cardiac tumour resection: 3-4 hours
LVAD implantation: 4-6 hours
Heart transplantation: 4-8 hours
PTE: 6-10 hours (complex procedure)
SVR (with CABG): 4-6 hours

16. Anaesthesia and Procedure Duration

Anaesthesia Type:

All procedures in this category are performed under general anaesthesia, meaning complete unconsciousness and no pain. Anaesthesia teams specialising in cardiac surgery manage complex cases.

Components:

Induction: IV medications (propofol, opioids, benzodiazepines) to induce unconsciousness
Airway management: Endotracheal tube (breathing tube) connected to mechanical ventilator
Maintenance: Inhaled anaesthetic gases (sevoflurane, desflurane) plus IV infusions
Analgesia: Strong pain medications (fentanyl, morphine) throughout and after surgery
Muscle relaxation: Paralytics to facilitate ventilation and surgical conditions
Monitoring: Continuous ECG, blood pressure (arterial line), oxygen saturation, temperature, anaesthesia depth monitoring, transesophageal echocardiography (TEE)

Special Monitoring:

Arterial line — continuous blood pressure monitoring
Central venous line — central pressures, medication administration
Pulmonary artery catheter — detailed cardiac function measurements (especially for heart failure cases)
TEE probe — real-time heart imaging during surgery
Near-infrared spectroscopy (NIRS) — brain oxygenation monitoring
Temperature monitoring — multiple sites (especially for PTE with deep hypothermia)

Duration:

Pericardiectomy: 3-5 hours surgical time, 4-6 hours total anaesthesia time
Pericardial window: 1-2 hours total
Cardiac tumour resection: 3-4 hours surgical time, 4-5 hours total
LVAD implantation: 4-6 hours surgical time, 5-7 hours total
Heart transplantation: 4-6 hours surgical time (can extend to 8+ for complex cases), 5-8 hours total
PTE: 6-10 hours surgical time (complex, meticulous dissection), 7-12 hours total
SVR with CABG: 4-6 hours surgical time, 5-7 hours total

Factors Extending Duration:

Previous cardiac surgery (redo operations)
Adhesions from prior surgery or inflammation
Complex anatomy or unexpected findings
Concomitant procedures (CABG, valve repair)
Intraoperative complications
Very large tumours or extensive disease

Special Anaesthetic Considerations:

PTE: Deep hypothermia (18-20°C) with circulatory arrest periods requires specialised anaesthetic management
Heart failure patients (LVAD/transplant): Sensitive to anaesthetic medications, careful dosing required
Transplant patients: May be critically ill before transplant, requiring meticulous hemodynamic management
Patients on anticoagulants: Careful management of bleeding and clotting

17. Technology, Devices and Equipment Used

Heart-Lung Machine (Cardiopulmonary Bypass):

Used for most procedures in this category (except some pericardial windows). Oxygenates blood outside body and returns it to circulation, allowing heart to be stopped for precise surgery. Consists of pumps, oxygenator, heat exchanger, filters, and reservoir.

Specialised Equipment by Procedure:

Pericardiectomy:

Oscillating saw for sternotomy
Retractors to hold chest open
Microsurgical instruments for delicate pericardial dissection
Electrocautery for controlling bleeding
Bones wax for sternal bleeding control

Cardiac Tumour Resection:

Cardioplegia delivery system — stops heart for tumour removal
Specimen retrieval bags — prevent tumour fragmentation/spreading
Patch materials for atrial septal closure (pericardial patch, synthetic patch)

LVAD Implantation:

LVAD device (HeartMate 3, HeartWare HVAD, or similar)
Inflow cannula — connects to left ventricle apex
Outflow graft — connects to aorta
External controller — device power and monitoring
Batteries — power source for mobile patients
Driveline — connects device through skin to controller

Heart Transplantation:

Potent immunosuppressant medications — started intraoperatively
Temporary pacemaker — common after transplant (heart rhythm instability)
Intra-aortic balloon pump — circulatory support if needed
ECMO — may be used for very ill patients pre- or intraoperatively

PTE:

Deep hypothermia equipment — cools patient to 18-20°C
Circulatory arrest management — specialised monitoring during no-flow periods
Microsurgical instruments — for delicate dissection in small pulmonary arteries
Suction devices — specialised for blood and material removal

SVR:

Ventricular reconstruction patch — synthetic or bovine pericardial patch
Circular suture devices — to size and shape ventricle
Standard CABG equipment — for concurrent bypass grafting

Imaging and Monitoring:

Transesophageal echocardiogram (TEE) — real-time heart imaging during surgery
Epicardial echocardiography — ultrasound probe on heart surface
Intravascular ultrasound — occasionally for device positioning
Fluoroscopy — X-ray imaging for some procedures

Postoperative Support Equipment:

Ventilator — breathing machine until adequate respiratory function
Intra-aortic balloon pump — circulatory support for weakened heart
ECMO — temporary heart-lung support for critically ill patients
Temporary pacemaker — for rhythm management
Dialysis machine — if kidney dysfunction postoperatively
Ventricular assist devices — bridge to recovery if heart dysfunction

Wound Closure and Dressing:

Sternum fixation systems — stainless steel wires, plates for complex cases
Chest drainage systems — tubes connected to suction canisters
Wound vacuum devices — for complex wound healing issues
Sterile dressings — various types for different wounds

18. Benefits of the Procedure

These procedures provide significant benefits for appropriately selected patients:

Pericardiectomy Benefits:

Dramatic symptom relief — reduced swelling, improved breathing, better appetite
Improved quality of life — return to normal activities
Reduced medications — less need for diuretics
Prevented liver dysfunction — from chronic venous congestion
Potential cure — for constrictive pericarditis (excellent long-term results)
Extended survival — compared to untreated constrictive pericarditis

Pericardial Window Benefits:

Prevents recurrent tamponade — life-threatening emergency prevented
Avoids repeated drainage procedures — permanent solution
Improves breathing — removing compression allows better lung function
Hospitalisation prevention — reduces emergency admissions for effusion

Cardiac Tumour Resection Benefits:

Prevents stroke — tumour fragments can travel to brain
Relieves obstruction — improves blood flow through heart
Eliminates arrhythmias — tumour can interfere with electrical system
Curative for benign tumours — complete removal usually curative
Improves survival — especially for malignant tumours when completely resectable

LVAD Benefits:

Life-saving — prevents death from end-stage heart failure
Improved quality of life — return to activities, reduced symptoms
Improved exercise capacity — device augments heart function
Bridge to transplant — keeps patient alive until donor available
Destination therapy — long-term option for non-transplant candidates
Improved organ function — better kidney and liver perfusion

Heart Transplant Benefits:

Life-saving — only option for some end-stage heart failure patients
Excellent quality of life — near-normal function for most recipients
Improved survival — 10+ years average survival
Return to normal activities — work, exercise, travel
Freedom from heart failure symptoms — no more swelling, breathing problems, fatigue
Psychological benefits — hope restored, new beginning

PTE Benefits:

Potentially curative for CTEPH — only curative treatment
Dramatic improvement in symptoms — breathing, exercise capacity
Normalised pulmonary pressures — reduces right heart strain
Improved right heart function — right heart recovers
Improved survival — compared to medical therapy alone
Reduced need for pulmonary hypertension medications

SVR Benefits:

Improved ventricular function — reconstructed ventricle pumps more efficiently
Reduced heart failure symptoms — less shortness of breath, swelling
Improved survival — compared to medical therapy for selected patients
Reduced arrhythmias — aneurysm can cause rhythm problems
Better quality of life — improved exercise tolerance

General Benefits Across Procedures:

Access to expert care — specialised centres provide optimal outcomes
Advanced technology — state-of-the-art devices and techniques
Comprehensive care — multidisciplinary teams address all aspects
Medical tourism advantages — significant cost savings for international patients

19. Success Rate and Expected Outcomes

Success rates vary considerably by specific procedure and patient factors:

Pericardiectomy Outcomes:

Operative mortality: 5-15% (higher in advanced cases, frail patients)
Symptom improvement: 80-90% experience significant or complete relief
Long-term survival: 70-80% at 5 years (varies by underlying cause)
Recurrence: 5-10% require repeat procedure for residual constriction
Best outcomes: when performed early before significant organ damage

Pericardial Window Outcomes:

Procedural success: >95% effective in preventing recurrence
Complications: 5-10% (bleeding, infection, wound issues)
Duration of benefit: Often permanent drainage pathway
Mortality: 1-3% (higher in critically ill or cancer patients)

Cardiac Tumour Resection Outcomes:

Operative mortality: 1-5% for benign tumours (myxoma), higher for malignant
Complete resection: >90% for myxomas
Recurrence: <5% for benign tumours, higher for malignant
Long-term survival: Excellent for benign tumours (near-normal life expectancy)
Stroke prevention: Eliminates tumour embolization risk

LVAD Outcomes:

30-day survival: 85-95% in experienced centres
1-year survival: 70-80% for destination therapy
2-year survival: 60-70% for modern continuous-flow devices
Bridge to transplant: 70-80% successfully bridge to transplant
Quality of life: Significant improvement for most survivors
Device durability: Modern devices 2-5 years average (some longer)

Heart Transplant Outcomes:

30-day survival: 90-95%
1-year survival: 85-90%
5-year survival: 70-75%
10-year survival: 50-60%
Quality of life: Excellent for most recipients (near-normal function)
Rejection: Acute rejection 20-30% (treatable), chronic rejection leading to graft vasculopathy

PTE Outcomes:

Operative mortality: 5-10% in experienced centres (higher in high-risk patients)
Significant symptom improvement: 80-90% of survivors
Normalised pulmonary pressures: 60-70% achieve near-normal pressures
5-year survival: 70-80% (compared to 30-50% with medical therapy)
Functional improvement: Most return to normal activities
Best outcomes: In specialised high-volume centres

SVR Outcomes:

Operative mortality: 5-10% (with concurrent CABG)
Symptom improvement: 70-80% experience significant improvement
Ejection fraction improvement: 5-10% absolute improvement average
5-year survival: 60-70% (selected patients)
Freedom from heart failure: 50-60% at 5 years

Factors Affecting Outcomes:

Centre and surgeon experience — high-volume centres have better outcomes
Patient selection — appropriate candidates have better results
Preoperative condition — sicker patients have higher risk
Completeness of procedure — complete treatment yields better results
Postoperative care — excellent follow-up improves outcomes
Patient adherence — medications, lifestyle changes crucial

Quality of Life: Most patients report significantly improved quality of life after these procedures. Return to work, normal activities, and psychological well-being commonly achieved. Recovery varies from weeks (pericardial window) to months (transplant, PTE).

20. Risks and Possible Complications

As with any major surgery, these procedures carry risks. However, in experienced centres, most complications are manageable:

Common Risks (5-20% occurrence):

Bleeding requiring reoperation — 5-10% may need return to operating room
Blood transfusion — 30-60% receive transfusion (varies by procedure and preoperative anaemia)
Atrial fibrillation — rapid irregular heart rhythm, very common after cardiac surgery
Wound infection — sternum or incision sites (2-5%, higher in diabetics, obese)
Pain — incision discomfort (managed with medications)
Kidney dysfunction — temporary in up to 10-20% (dialysis needed in 1-3%)

Serious Risks (1-5% occurrence):

Stroke — 1-3% risk (higher in elderly, those with carotid disease, previous stroke)
Heart attack during surgery — <1-2%
Low cardiac output syndrome — weakened heart requiring medications or mechanical support
Sternal wound complications — dehiscence (wound separation) or infection (mediastinitis) in 1-3%
Respiratory failure — pneumonia, prolonged ventilation (especially in lung disease patients)
Deep vein thrombosis (DVT) or pulmonary embolism — blood clots

Procedure-Specific Risks:

Pericardiectomy:

Phrenic nerve injury — 5-10% (causes diaphragm paralysis, breathing difficulty)
Bleeding from dense adhesions — pericardium stuck to heart, liver, other structures
Ventricular injury — accidental hole in heart muscle during dissection
Incomplete relief — residual constriction (5-10%)

Cardiac Tumour Resection:

Tumour fragmentation — pieces breaking off, causing emboli
Incomplete resection — tumour left behind
Heart block — damage to electrical system requiring pacemaker
Valve damage — during tumour removal

LVAD:

Bleeding — common due to blood thinners required
Stroke — 5-10% (device causes blood clots)
Infection — 20-30% (driveline exit site, device, or pump infection)
Device thrombosis — clot forming in device
Right heart failure — LVAD can worsen right heart function
Hemolysis — red blood cell damage from device

Heart Transplant:

Rejection — acute (20-30%), chronic (gradual graft vasculopathy)
Infection — increased risk from immunosuppression
Kidney dysfunction — from immunosuppressant medications
Malignancy — increased cancer risk from immunosuppression
Primary graft dysfunction — donor heart doesn’t work properly initially
Coronary artery disease in donor heart — accelerated atherosclerosis

PTE:

Bleeding — from extensive dissection
Residual pulmonary hypertension — incomplete removal of clot material
Reperfusion lung injury — lung swelling from restored blood flow
Neurological injury — from deep hypothermia or circulatory arrest
Right heart failure — during or after procedure

SVR:

Low cardiac output — initially after reconstruction
Ventricular rupture — rare but serious
Residual heart failure — procedure may not adequately improve function
Arrhythmias — ventricular tachycardia

Rare but Severe Risks (<1%):

Death — varies by procedure (1-10% overall)
Multiorgan failure — in very high-risk patients
Permanent stroke — lasting disability
Permanent cognitive dysfunction — memory problems

Risk Reduction:

Preoperative optimisation of medical conditions
Experienced surgeon and hospital
Meticulous surgical technique
Prophylactic medications (antibiotics, beta-blockers)
Early mobilization and respiratory therapy
Careful postoperative monitoring
Patient education and adherence

Most complications are treatable, and the overall risk-benefit ratio strongly favours these procedures for appropriate candidates.

21. Hospital Stay and Immediate Aftercare

Immediate Postoperative Period (Day 0-1):

Patient transferred from operating room to Cardiovascular Intensive Care Unit (CVICU) for close monitoring:

Ventilator support — breathing tube remains for several hours until patient awakens adequately
Monitoring — continuous ECG, arterial line (blood pressure), oxygen saturation, chest tubes draining, urinary catheter measuring output
Medications — pain control, antibiotics, blood thinners (as appropriate), heart medications, sedation if agitated
Breathing exercises — incentive spirometer to prevent lung collapse/pneumonia
Early mobilization — sat up in chair, walked to chair within 12-24 hours (reduces complications)
Device-specific care — LVAD management, transplant immunosuppression

Procedure-Specific Immediate Care:

Pericardiectomy:

Aggressive diuresis initially to remove retained fluid
Careful monitoring for bleeding from dissection sites
Phrenic nerve function assessment (diaphragm movement)

LVAD:

Device monitoring — continuous pump parameters, flow rates
Anticoagulation management — heparin transitioned to warfarin
Driveline care — exit site dressing changes
Caregiver training begins when patient stable

Heart Transplant:

Immunosuppression — high-dose initially (methylprednisolone, tacrolimus, mycophenolate)
Rejection monitoring — biopsies scheduled (weekly initially)
Infection prophylaxis — antibiotics, antifungals, antivirals
Donor heart function monitoring — echocardiography, hemodynamics

PTE:

Lung management — careful ventilation, possible reperfusion lung injury
Pulmonary artery pressure monitoring — assess success of procedure
Bleeding monitoring — extensive dissection surfaces

Progression (Day 2-3):

Breathing tube removed, patient breathing independently
Chest tubes removed when drainage minimal
Pacing wires removed (if present) once rhythm stable
Transferred to step-down unit or cardiac ward
Increased activity — walking in halls, stairs
Pain management transitioned to oral medications
Diet advanced as tolerated
Education on wound care, activity restrictions, medications

Preparing for Discharge (Day 4-21):

Pain controlled with oral medications
Bowel function returned
Ambulating independently
Incisions healing well
Discharge teaching completed
Medications reviewed
Follow-up appointments scheduled
Arrangements for home care or cardiac rehabilitation made

Typical Hospital Stay:

Pericardial window: 3-5 days
Pericardiectomy: 5-7 days
Cardiac tumour resection: 4-6 days
LVAD implantation: 10-14 days (including caregiver training)
Heart transplant: 14-21 days (monitoring for rejection, infection)
PTE: 10-14 days (often with ICU stay 3-5 days)
SVR: 5-7 days (similar to CABG)

May extend for complications or complex cases.

22. Recovery Timeline

First 2 Weeks at Home:

Fatigue — expect to tire easily, need rest periods
Incision care — keep clean and dry, shower per surgeon’s instructions (usually 5-7 days post-op)
Activity restrictions — no lifting >5-10 lbs, no driving (usually 4-6 weeks), no pushing/pulling
Pain management — prescription pain medications tapered as needed
Sleep — may sleep better reclined or with extra pillows
Appetite — may be reduced initially, but nutrition important for healing
Emotional — mood swings, depression, anxiety common (normal response)

Procedure-Specific Recovery:

Pericardiectomy:

Gradual improvement in breathing and swelling over 2-4 weeks
Diuretics may still be needed temporarily
Energy levels improve steadily

LVAD:

Caregiver essential — driveline care, device monitoring, alarm response
No driving while carrying device (most centres prohibit driving)
Battery management — always carry spare batteries
Anticoagulation — warfarin daily, INR monitoring
Regular device checks — transmit data to centre regularly

Heart Transplant:

Frequent clinic visits — initially weekly, gradually spaced
Biopsies — weekly initially to monitor rejection
Immunosuppression — strict medication adherence critical
Infection avoidance — avoid sick people, crowded places initially
Activity progression — gradual return to normal over 3-6 months

PTE:

Gradual improvement in breathing over weeks to months
Pulmonary rehabilitation — often helpful
Exercise progression — slow but steady improvement

Weeks 2-6:

Gradually increase walking and light activity
Begin cardiac rehabilitation if prescribed (typically 3-6 weeks post-op)
Driving permitted when sternum healed and off narcotics (typically 4-6 weeks)
Lifting restriction gradually increased
Return to sedentary work possible at 4-6 weeks for many
Less pain in incisions, more energy

Weeks 6-12:

Return to normal daily activities for most patients
Light housework, short shopping trips
Sexual activity can usually resume (6-8 weeks)
Strenuous exercise and heavy lifting still restricted
LVAD/transplant: continue regular follow-up, device monitoring, medication adherence

3-6 Months:

Full recovery — return to all normal activities including vigorous exercise for most
Healing complete — sternum fully healed (3-6 months for bone solidification)
Cardiac rehabilitation completion — typically 12-week program
Return to work — including physically demanding jobs
Feel like “normal self” — full energy, exercise tolerance
Transplant: immunosuppression stable, clinic visits less frequent
LVAD: established routine with device

12 Months:

Maximum recovery achieved
Long-term maintenance phase begins
Transplant: yearly coronary angiography to monitor for donor heart CAD
LVAD: device monitoring, medication management, consideration of transplant suitability
PTE: continued improvement possible up to 1-2 years

Factors affecting recovery: age, preoperative fitness, complications, postoperative rehab participation, motivation, support system, procedure complexity.

23. Pain Management and Wound Care

Pain Management:

Immediately postoperative:

Epidural catheter or IV patient-controlled analgesia (PCA) for first 24-48 hours
Non-opioid options: acetaminophen, NSAIDs (caution with bleeding risk), gabapentin for nerve pain
Opioids: morphine, hydromorphone, oxycodone for moderate-severe pain

Transition to oral medications:

Combination: acetaminophen + opioid (oxycodone/acetaminophen) for breakthrough pain
Gradual taper over 2-4 weeks as pain decreases
Over-the-counter options (acetaminophen) for mild discomfort
Ice packs to incision sites for comfort

Procedure-Specific Considerations:

Pericardiectomy:

Chest discomfort from sternotomy
May have upper abdominal discomfort from diaphragm manipulation
Pain usually resolves by 4-6 weeks

LVAD/Transplant:

Similar sternotomy pain management
Additional pain from driveline exit site (LVAD)
May have longer hospital course requiring IV pain medications

Long-term:

Most patients off prescription pain medications by 4-6 weeks
Some residual numbness or tingling around incisions (normal, may persist)
Chronic pain after cardiac surgery uncommon

Wound Care:

Sternal Incision (chest):

Keep clean and dry until first postoperative visit (5-7 days)
Sterile strips (Steri-Strips) or glue used — let fall off naturally
No submerging in baths, pools, hot tubs until fully healed
Shower per surgeon instructions (usually allow after 5-7 days, let soapy water run over, pat dry)
Support with pillow when coughing, sneezing, or moving
Report: redness, drainage, opening, fever, increasing pain

Additional Incisions:

LVAD Driveline Site:

Specialised care required
Keep clean and dry
Dressing changes as instructed
Monitor for infection (redness, drainage)
Caregiver trained on care

Thoracotomy Incisions (if used):

Similar care to sternotomy
May be on side or back
Support with pillow when coughing

Leg Incisions (if vein harvesting):

Support stockings (TED hose) worn for 2-6 weeks
Elevate legs when sitting
Ankle and foot exercises
Expect swelling, bruising, numbness — normal

Red Flags requiring immediate medical attention:

Drainage from incisions (pus, clear fluid)
Separation of wound edges
Redness spreading around incision
Fever > 101°F (38.3°C)
Increasing pain not relieved by medication
LVAD: redness/purulence at driveline exit site

24. Medications After the Procedure

Medication regimens vary significantly by procedure:

Pericardiectomy Medications:

Diuretics (furosemide) — may continue temporarily to remove residual fluid, then tapered
Pain medications — tapered over 2-4 weeks
No long-term cardiac medications typically required (unless other heart conditions present)

Cardiac Tumour Resection Medications:

Pain medications — tapered over 2-4 weeks
No long-term cardiac medications typically required (unless other heart conditions present)

LVAD Medications:

Warfarin (Coumadin) — blood thinner, INR target 2.0-3.0 (prevents device clotting)
Aspirin — additional antiplatelet (81-325mg daily)
Beta-blockers — reduce arrhythmia risk
ACE inhibitors — may help right heart function
Diuretics — manage fluid
Digoxin — may be used for atrial fibrillation
Statins — cholesterol management
Gastric protection — PPIs for bleeding prevention with blood thinners

Heart Transplant Medications (Life-long):

Calcineurin inhibitors — tacrolimus (Prograf) or cyclosporine (primary immunosuppressants)
Antimetabolites — mycophenolate mofetil (CellCept) or azathioprine
Corticosteroids — prednisone (tapered to low maintenance dose)
mTOR inhibitors — sirolimus or everolimus (sometimes used)
Antibiotics/antivirals/antifungals — prophylaxis (trimethoprim-sulfamethoxazole, acyclovir/valganciclovir)
Blood pressure medications — calcium channel blockers, ACE inhibitors (common side effect of immunosuppressants)
Diuretics — fluid management
Statins — prevent donor heart CAD
Gastric protection — PPIs (stress ulcer prevention)
Antifungal mouthwash — prevent thrush

PTE Medications:

Pulmonary hypertension medications — may continue or be reduced depending on response
Diuretics — may continue temporarily
Anticoagulation — often continued (warfarin) for pulmonary hypertension
Blood pressure medications — as needed

SVR Medications:

Standard heart failure medications — similar to post-CABG:
- Aspirin — lifelong
- Statin — lifelong
- Beta-blockers — lifelong
- ACE inhibitors/ARBs — lifelong
- Aldosterone antagonists — if reduced ejection fraction
- Diuretics — as needed for fluid
- Antiarrhythmics — if needed

General Medication Principles:

Never stop medications without consulting doctor
Keep list of all medications
Report side effects
Organize with pillbox
Understand purpose of each medication
Transplant/LVAD: strict adherence critical — missed doses can be fatal

Potential Side Effects:

Warfarin: bleeding, bruising, interacts with many foods/medications
Tacrolimus: kidney dysfunction, tremor, high blood pressure, diabetes
Prednisone: weight gain, mood changes, osteoporosis, diabetes, cataracts
Statins: muscle pain, liver enzyme elevation
Beta-blockers: fatigue, dizziness, slow heart rate
Diuretics: frequent urination, electrolyte abnormalities

25. Diet, Exercise and Lifestyle Guidelines

Dietary Recommendations:

Heart-Healthy Diet (Mediterranean-style):

Emphasis on: vegetables, fruits, whole grains, legumes, nuts, olive oil
Fish 2-3 times weekly (omega-3 fatty acids)
Lean protein — chicken, turkey, plant proteins
Low-fat dairy — skim milk, yogurt, limited cheese

Foods to Limit:

Saturated fats — red meat, butter, full-fat dairy
Trans fats — partially hydrogenated oils
Sodium — <2,000 mg daily (especially important for heart failure patients)
Added sugars — sodas, candies, desserts
Processed meats — bacon, sausage, hot dogs

Procedure-Specific Considerations:

LVAD/Heart Failure:

Fluid restriction — often 1.5-2 liters daily
Sodium restriction — strict (<2,000 mg, sometimes <1,500 mg)
Daily weights — report gain >1-2 kg in a day or >2 kg in a week
Potassium monitoring — if on diuretics

Heart Transplant:

Food safety — increased infection risk, avoid raw foods, undercooked meats
No grapefruit juice — interacts with tacrolimus
Healthy weight management — prednisone increases appetite
Calcium and Vitamin D — prevent steroid-induced osteoporosis

PTE:

Healthy diet — overall heart health
Sodium moderation — if right heart failure present

Exercise Guidelines:

Early Phase (0-6 weeks):

Walking program — start 5-10 minutes, gradually increase
Avoid heavy lifting (>5-10 lbs)
No strenuous exercise
Stop for chest pain, excessive shortness of breath, dizziness
LVAD: light activity as tolerated, no driving

Intermediate Phase (6-12 weeks):

Increase walking to 30 minutes daily
Light stationary bike
Begin cardiac rehabilitation program
Transplant: gradually increase activity

Long-term (3+ months):

Aerobic exercise — walking, jogging, cycling, swimming (30-60 minutes, 5 days/week)
Resistance training — light weights, 2-3 days/week (after sternum fully healed)
Flexibility/balance — stretching, yoga (modify to avoid sternum pressure)

Procedure-Specific Exercise:

LVAD:

Walking encouraged — excellent exercise, device allows
No swimming or soaking — device and driveline must stay dry
No contact sports — risk of device damage
Avoid activities that strain driveline — heavy lifting, twisting

Heart Transplant:

Gradual return to normal activity over 3-6 months
Exercise excellent — prevents rejection, improves heart function
No contact sports initially — until steroid dose reduced and wound healed
Most activities possible long-term — once stable

Lifestyle Modifications:

Smoking Cessation:

Complete cessation — most critical lifestyle change
Resources: counseling, nicotine replacement, medications
Transplant: smoking absolutely contraindicated (causes rejection, CAD)

Alcohol:

Moderate intake (≤1 drink/day for women, ≤2 for men)
Transplant: caution with alcohol — interacts with medications, liver toxicity
LVAD: caution — can affect anticoagulation

Stress Management:

Relaxation techniques, meditation, deep breathing
Adequate sleep (7-9 hours nightly)
Counseling/therapy if depression or anxiety

Sexual Activity:

Usually resume 6-8 weeks post-op (when sternum healed)
LVAD: resume when medically cleared (usually 6-8 weeks), position considerations
Transplant: resume when medically cleared and wound healed
Stop for chest pain, shortness of breath

Travel:

LVAD: require planning — batteries, equipment, medical letter
Transplant: avoid high-risk areas initially (infection risk), carry medications
PTE: improve breathing allows travel

26. Cardiac Rehabilitation

Cardiac rehabilitation is a medically supervised program designed to help patients recover after cardiac surgery. Participation is strongly recommended and associated with better outcomes:

Program Structure:

Typically 12 weeks (36 sessions)
3 sessions per week
Combination of exercise training, education, and counseling
Covered by most insurance plans
LVAD/Transplant: specialised programs available

Exercise Component:

Initial assessment — fitness testing, ECG-monitored exercise
Individualized exercise prescription — aerobic and resistance training
Supervised sessions — telemetry monitoring, blood pressure checks
Progressive intensity — gradually increasing duration and intensity
Home exercise program — instructions for days between sessions

Educational Topics:

Heart anatomy and disease process
Explanation of specific procedure
Medication purpose and side effects
Nutrition counseling
Stress management techniques
Smoking cessation support
Return to work guidance
Sexual activity considerations

Procedure-Specific Rehabilitation:

LVAD Rehabilitation:

Exercise safe and beneficial — device supports heart during exercise
Focus on endurance — improve walking distance
Caregiver education — included in rehab programs
Device management during exercise — battery management, activity with equipment

Transplant Rehabilitation:

Gradual progression — initially deconditioned from illness
Excellent outcomes — most return to normal activity
Anti-rejection medication education
Infection prevention strategies

PTE Rehabilitation:

Focus on respiratory function — breathing exercises
Gradual improvement — lung healing continues for months
Endurance training — improve exercise capacity

Benefits of Participation:

Improved exercise capacity and functional status
Reduced symptoms — less shortness of breath, less fatigue
Better medication adherence
Weight management
Psychosocial support — meet others with similar experiences
Reduced depression and anxiety
Lower mortality and hospital readmission (30-40% reduction)

Phases of Cardiac Rehabilitation:

Phase I (Inpatient):

Begins in hospital
Range-of-motion exercises, walking
Education on recovery and home care

Phase II (Outpatient):

Supervised program as described above
Starts 2-6 weeks after discharge
Telemetry monitoring for safety

Phase III (Maintenance):

Transition to independent exercise
Less frequent supervision
Community-based or gym-based continuation

Finding a Program:

Hospital social workers or case managers provide referrals
Programs available at most hospitals and cardiac centers
Transportation assistance often available
LVAD/Transplant: ask about specialised cardiac rehab programs

27. Follow-Up Tests and Long-Term Monitoring

Follow-up varies considerably by procedure:

Pericardiectomy Follow-Up:

2-4 weeks: surgical follow-up, wound check, symptom assessment
3 months: echocardiogram to assess heart function
6-12 months: clinical assessment, repeat echocardiogram if needed
Long-term: annual or as needed if symptoms recur

Cardiac Tumour Resection Follow-Up:

2-4 weeks: surgical follow-up
3-6 months: echocardiogram to confirm no residual tumour
Yearly: echocardiogram for benign tumours; more frequent for malignant

LVAD Follow-Up:

Frequent initially: weekly or biweekly for first 1-2 months
Device monitoring: regular data transmission to centre
Blood tests: weekly INR initially, then biweekly, monthly (warfarin monitoring)
3 months: echocardiogram, right heart catheterisation
6 months: device assessment, echocardiogram
Yearly: comprehensive assessment including echocardiogram, right heart catheterisation
Ongoing: pump parameters, driveline site assessment, medication review

Heart Transplant Follow-Up:

Very frequent initially: weekly clinic visits with biopsy for first month
2-3 months: biweekly clinic visits with biopsies
3-6 months: monthly clinic visits with biopsies
6-12 months: clinic visits every 1-3 months, biopsies less frequent
Yearly: coronary angiography to monitor for donor heart CAD
Ongoing: regular blood tests for immunosuppressant levels, kidney function, liver function, infection surveillance
Long-term: annual or biannual coronary angiography, regular clinic visits

PTE Follow-Up:

2-4 weeks: surgical follow-up
3 months: echocardiogram, right heart catheterisation to assess pulmonary pressures
6-12 months: repeat right heart catheterisation
Yearly: clinical assessment, echocardiogram
Long-term: monitor for recurrent pulmonary hypertension

SVR Follow-Up:

Similar to CABG follow-up
2-4 weeks: surgical follow-up
6-8 weeks: cardiology visit, ECG, medication review
3-6 months: stress test, echocardiogram
Yearly: annual assessment, stress testing, echocardiogram

Patient Responsibilities:

Keep all scheduled appointments
Report new symptoms promptly
Maintain medication diary
Monitor vital signs at home (weight, blood pressure, device parameters for LVAD)
Keep records of all tests and procedures
LVAD: transmit device data regularly
Transplant: report any signs of infection or rejection

Communication:

Ensure all healthcare providers aware of procedure and medications
Wear medical alert bracelet (LVAD, transplant)
Carry list of medications and allergies
Transplant: carry transplant card
LVAD: carry device information card

28. Warning Signs After the Procedure

Patients should be educated to recognize and promptly report concerning symptoms:

Red Flags — Seek Immediate Medical Attention:

Chest Symptoms:

New or worsening chest pain, pressure, or discomfort
Pain not relieved by rest or prescribed medications
Crushing, heavy sensation in chest

Heart Attack Symptoms:

Chest pain radiating to arm, neck, jaw, or back
Cold sweats, nausea, vomiting
Severe shortness of breath
Light-headedness or loss of consciousness

Infection Signs:

Fever > 101°F (38.3°C) or chills
Redness, warmth, or swelling around incisions or driveline site (LVAD)
Pus or foul-smelling drainage from wounds
Opening or separation of wound edges

Breathing Problems:

Sudden severe shortness of breath at rest
Difficulty breathing not improving with rest
Coughing up blood or pink frothy sputum
Wheezing or chest tightness

Neurological Symptoms (Stroke Warning):

Sudden weakness or numbness in face, arm, or leg (especially one-sided)
Difficulty speaking or understanding speech
Vision changes (double vision, loss of vision)
Severe headache, dizziness, loss of balance/coordination

Heart Rhythm Issues:

Rapid, irregular heartbeat or palpitations
Feeling of racing heart, skipped beats, or extra beats
Slow heart rate (<50) or very fast (>120 at rest)
Dizziness or fainting with rhythm changes

Procedure-Specific Warning Signs:

LVAD Warning Signs:

Device alarms — red alarms require immediate attention
Decreased pump flow — as displayed on device controller
Red blood in urine or stool — suggests bleeding
Driveline redness/purulence — infection
Headache, neurological symptoms — stroke
Sudden weight gain — fluid retention, pump dysfunction

Transplant Warning Signs:

Shortness of breath — possible rejection
Fever — infection or rejection
Fatigue — possible rejection
Palpitations — possible rejection
Flu-like symptoms — infection or rejection
Decreased urine output — kidney dysfunction

General Concerning Symptoms:

Sudden severe leg swelling or pain (possible DVT)
Fainting or loss of consciousness
Severe headache unlike usual
Mental status changes (confusion, extreme fatigue)
Sudden weight gain (2-3 kg in a week) — fluid retention

When to Call Doctor (Not Emergency, but Prompt):

Mild discomfort at incision sites increasing over days
Persistent low-grade temperature
Questions about medications
Insomnia, depression, anxiety affecting recovery
Medication side effects
LVAD: yellow device alarms (generally non-urgent but requires attention)
Transplant: questions about medications, mild symptoms

Emergency Preparedness:

Keep phone numbers for cardiologist, surgeon, and primary care accessible
Know when to call 911 vs. doctor’s office
Have list of all medications and medical history available
LVAD: carry emergency information card, always have spare batteries
Transplant: carry transplant card, emergency contact numbers

Better to over-report symptoms than delay — early intervention for complications yields better outcomes.

29. Long-Term Results and Procedure Durability

Long-term results vary considerably by specific procedure:

Pericardiectomy Long-Term Results:

Excellent durability — for idiopathic or viral constrictive pericarditis
5-year survival: 70-80%
10-year survival: 60-70% (varies by underlying cause)
Recurrence: 5-10% develop recurrent constriction
Symptom relief: 80-90% maintain long-term improvement
Best outcomes: when performed early, before significant organ damage

Cardiac Tumour Resection Long-Term Results:

Excellent for benign tumours: cure expected with complete resection
Myxoma: <5% recurrence rate, near-normal life expectancy
Malignant tumours: variable outcomes, depends on tumour type and completeness of resection
Long-term survival: excellent for benign, guarded for malignant
Stroke prevention: tumour removal eliminates embolization risk

LVAD Long-Term Results:

Device durability: 2-5 years average (modern devices)
Survival: 60-80% at 2 years, 50-70% at 3 years for destination therapy
Bridge to transplant: 70-80% successfully bridge to transplant
Quality of life: significant improvement for most survivors
Complications over time: infection, bleeding, stroke, device malfunction
Pump exchange: may be required if device fails (5-10% per year)

Heart Transplant Long-Term Results:

Half-life of graft: approximately 10-12 years
1-year survival: 85-90%
5-year survival: 70-75%
10-year survival: 50-60%
20-year survival: 20-30%
Quality of life: excellent for most recipients
Limiting factors: chronic rejection (graft vasculopathy), malignancy, infection
Re-transplantation: possible for graft failure (higher risk than first transplant)

PTE Long-Term Results:

Excellent for suitable candidates: often curative
5-year survival: 70-80% (compared to 30-50% with medical therapy)
Symptom relief: 80-90% experience significant improvement
Pulmonary pressures: often normalise or significantly improve
Functional improvement: most return to normal activities
Recurrence: uncommon (<10%)

SVR Long-Term Results:

5-year survival: 60-70%
Freedom from heart failure: 50-60% at 5 years
Ventricular function: 5-10% absolute improvement in ejection fraction
Symptom relief: 70-80% experience significant improvement
Need for transplant/LVAD: 20-30% eventually require advanced therapies
Recurrence of aneurysm: uncommon

Factors Affecting Long-Term Success:

General Factors:

Patient selection — appropriate candidates have best results
Centre experience — high-volume centres have better outcomes
Procedure completeness — complete treatment yields better results
Postoperative care — excellent follow-up improves outcomes
Patient adherence — medications, lifestyle changes crucial

Transplant-Specific Factors:

Immunosuppression adherence — critical for long-term graft survival
Rejection episodes — treated rejection usually doesn’t affect long-term outcomes significantly
Donor heart CAD — major long-term complication
Malignancy — increased risk from immunosuppression
Kidney dysfunction — from immunosuppressant medications

LVAD-Specific Factors:

Device management — proper care, monitoring improves outcomes
Anticoagulation adherence — prevents device thrombosis
Infection prevention — driveline care critical
Nutritional status — maintains strength and healing

What Happens if Procedures Fail:

Pericardiectomy: may require repeat procedure if recurrent constriction
LVAD: pump exchange if device fails; consideration of transplant
Transplant: re-transplantation for graft failure (higher risk)
PTE: medical therapy for residual pulmonary hypertension
SVR: medical therapy, transplant, or LVAD for recurrent heart failure

30. Repeat Procedure and Reintervention

Some patients may require additional procedures after initial surgery:

Need for Reintervention by Procedure:

Pericardiectomy:

5-10% develop recurrent constriction
May require repeat pericardiectomy (higher risk, more adhesions)
Pericardial window if not candidate for repeat surgery
Medical management if not surgical candidate

Cardiac Tumour Resection:

Recurrence uncommon for benign tumours (<5%)
Reoperation for recurrent tumours
Malignant tumours: higher recurrence rates, may require repeat resection or other treatments
Regular monitoring with echocardiography to detect recurrence

LVAD:

Pump exchange if device fails (5-10% per year)
Upgrade to newer device when technology advances
Transplant if suitable candidate emerges
Right ventricular assist device (RVAD) if right heart failure develops
Pump thrombosis treatment: thrombolysis, pump exchange

Heart Transplant:

Re-transplantation for graft failure (chronic rejection, graft vasculopathy)
Higher risk than first transplant (mortality 10-15%)
Limited donor availability — may not be feasible
LVAD as bridge to re-transplantation
Medical management of rejection, graft vasculopathy

PTE:

Repeat PTE rarely needed (<5%)
Residual hypertension managed medically
Lung transplantation for end-stage CTEPH not amenable to PTE
Medical therapy for pulmonary hypertension

SVR:

Transplant or LVAD if recurrent heart failure
Repeat SVR uncommon (ventricle may not be suitable)
Medical management of heart failure symptoms

Options for Reintervention:

Surgical Options:

Repeat procedures — higher risk, technically more challenging due to adhesions
Alternative procedures — transplant for failed SVR/LVAD
Device exchange — LVAD pump replacement

Medical Management:

Intensified medical therapy — for recurrent heart failure
Pulmonary hypertension medications — for residual CTEPH
Immunosuppression — for transplant rejection

Timing of Reintervention:

Early (<1 year): usually technical issues or inadequate initial treatment
Late (1-5 years): disease progression, device failure, graft vasculopathy
Very late (>5 years): wear and tear, chronic changes

Factors Influencing Decision:

Patient age and overall health
Previous surgery complexity
Current symptoms and functional status
Donor availability (for transplant)
Patient preference
Quality of life considerations

Outcomes After Reintervention:

Generally higher risk than initial procedure
Good symptom relief possible in selected patients
Careful patient selection crucial
Experienced centres essential for complex redo procedures

Preventing Reintervention:

Adequate initial procedure (complete treatment)
Aggressive risk factor modification after procedure
Medication adherence
Regular follow-up and monitoring
Early intervention for problems

31. Cost of the Procedure

Costs vary significantly by specific procedure, country, hospital, and case complexity. Medical tourism offers substantial cost savings for international patients:

Procedure	Country/Region	Approximate Cost Range (USD)
Pericardiectomy	United States	$40,000 - $80,000
	United Kingdom	£15,000 - £25,000 ($19,000 - $32,000)
	India	$6,000 - $12,000
	Turkey	$8,000 - $15,000
	Thailand	$9,000 - $16,000
Pericardial Window	United States	$15,000 - $30,000
	India	$4,000 - $8,000
	Turkey	$5,000 - $10,000
	Thailand	$6,000 - $11,000
Cardiac Tumour Resection	United States	$50,000 - $100,000
	India	$8,000 - $18,000
	Turkey	$10,000 - $20,000
	Thailand	$12,000 - $22,000
LVAD Implantation	United States	$150,000 - $300,000+
	India	$40,000 - $80,000
	Turkey	$50,000 - $90,000
	Thailand	$60,000 - $100,000
Heart Transplantation	United States	$1,000,000 - $1,500,000+
	India	$200,000 - $350,000
	Turkey	$250,000 - $400,000
	Thailand	$300,000 - $450,000
	Singapore	$350,000 - $500,000
PTE	United States	$100,000 - $200,000
	India	$25,000 - $50,000
	Turkey	$30,000 - $60,000
	Thailand	$35,000 - $65,000
SVR (with CABG)	United States	$60,000 - $120,000
	India	$12,000 - $25,000
	Turkey	$15,000 - $30,000
	Thailand	$18,000 - $35,000

Note: These are approximate ranges and vary by hospital, surgeon, case complexity, and complications. Transplant costs include pre-transplant evaluation, surgery, and initial post-transplant care but exclude long-term medications.

What’s Typically Included:

Preoperative diagnostic tests
Surgeon and anaesthesiologist fees
Operating room and hospital stay
Standard medications during hospitalization
Follow-up visits during initial stay
Transplant: initial immunosuppression, initial intensive care
LVAD: device cost, initial controller and batteries

Additional Costs:

Preoperative tests not recently performed
Prolonged ICU stay (complications, slow recovery)
Medications for home after discharge
Transplant: long-term immunosuppressants ($2,000-$4,000 monthly)
LVAD: ongoing anticoagulation monitoring, device replacements
Cardiac rehabilitation program
Flights and accommodation for medical tourists
Complications management
Lost wages from work

Insurance Considerations:

Many insurance plans cover medically indicated procedures
Preauthorization typically required
Transplant: often covered by insurance in many countries
LVAD: often covered as bridge to transplant, variable for destination therapy
Medical tourism costs often not covered by domestic insurance
Some international insurance plans cover care in multiple countries

Value Considerations:

Higher cost doesn’t always mean better outcomes
Experienced high-volume centres often have better results despite moderate costs
JCI-accredited hospitals demonstrate quality standards
Transplant: outcomes correlate with centre volume and experience
Consider total value, not just price

32. Factors Affecting Procedure Cost

Multiple variables influence pricing for these procedures:

Procedure-Specific Factors:

Complexity — PTE and transplant most expensive; pericardial window least expensive
Device costs — LVAD and transplant involve expensive devices/medications
Hospital stay length — transplant and PTE require longest stays
ICU requirements — most procedures require ICU but duration varies

Patient Factors:

Case complexity — unexpected findings, difficult anatomy
Comorbidities — diabetes, kidney disease, lung disease increase costs
Age — older patients may require more extensive monitoring
Emergency status — emergent procedures cost 30-50% more
Redo surgery — repeat procedures significantly more expensive
Nutritional status — malnutrition increases complication risk

Hospital Factors:

Geographic location — costs vary by region and country
Hospital type — academic centres, private hospitals vary in pricing
Accreditation — JCI-accredited centres may charge premium
Technology availability — advanced equipment increases cost
Volume — high-volume centres may have better pricing efficiency
Transplant centre designation — requires special certification

Surgeon Factors:

Surgeon experience and reputation — senior specialists often charge more
Surgical approach — minimally invasive techniques may cost more or less
Procedure duration — longer OR time increases cost

Transplant-Specific Cost Factors:

Donor organ acquisition — variable costs for organ procurement
Waiting time — prolonged hospitalisation while waiting for donor
Rejection episodes — treated with additional medications, procedures
Long-term immunosuppression — major ongoing cost ($2,000-$4,000 monthly)
Frequent monitoring — biopsies, lab tests, clinic visits

LVAD-Specific Cost Factors:

Device cost — major component of total cost
Anticoagulation management — frequent INR monitoring
Device replacements — pump exchange if fails
Driveline complications — infection treatment
Battery replacements — ongoing cost

Operative Factors:

Procedure duration — longer OR time increases cost
Complications — any complication significantly increases cost
ICU stay length — each additional day adds cost
Blood transfusion needs — blood products add expense
Concomitant procedures — combined procedures more expensive

Additional Cost Components:

Preoperative testing — extensive workup may be needed
Medications — expensive drugs (immunosuppressants, inotropes)
Diagnostic imaging — additional CT, MRI studies
Extended stay — each additional hospital day costs
Rehabilitation — cardiac rehabilitation program costs
Follow-up care — ongoing appointments and testing

Medical Tourism Specifics:

Travel expenses — flights, accommodation, meals
Visa and documentation
Language interpretation services
Local transportation
Complications treatment — postoperative care if needed
Return travel for follow-up — sometimes recommended
Accommodation for family — during hospitalisation and recovery

Cost-Saving Strategies:

Select high-volume centres (better outcomes, efficient care)
Medical tourism (50-90% savings in many countries)
Obtain detailed cost estimates beforehand
Understand what’s included vs. additional charges
Consider total value, not just price
Transplant: some countries have government funding or special programs

Insurance and Financing:

Verify insurance coverage and preauthorization requirements
Many hospitals offer payment plans for self-pay patients
Some medical tourism facilitators offer package pricing
Health savings accounts may be used in some countries
Transplant: many countries have national health services or special transplant funds

33. Choosing the Best Hospital and Specialist

Selecting the right hospital and surgeon is critical for optimal outcomes, especially for these complex procedures:

Hospital Selection Criteria:

Volume and Experience:

High-volume centres — hospitals performing >50-100 complex cardiac procedures annually have better outcomes
Established program — long-standing cardiac surgery departments with proven track record
Multidisciplinary team — cardiologists, cardiac surgeons, intensivists, rehabilitation specialists, infectious disease specialists (for transplant/LVAD)
Transplant centre designation — for transplant and LVAD programmes, requires special certification and volume requirements
PTE expertise — very few centres worldwide perform PTE regularly; seek experienced centres

Accreditation and Quality:

JCI accreditation (Joint Commission International) — international quality certification
National accreditation — equivalent national certifications
Outcomes data — publicly reported mortality and complication rates
Infection control programs — low surgical site infection rates
Transplant outcomes — UNOS or national registry data showing survival rates

Facilities and Technology:

Modern operating rooms — up-to-date equipment and technology
Advanced ICU — specialised cardiac intensive care unit
Hybrid capabilities — for combined procedures if needed
Emergency capabilities — 24/7 cardiac surgery coverage
Rehabilitation program — on-site cardiac rehabilitation
Transplant infrastructure — dedicated transplant unit, immunology laboratory
LVAD program — device expertise, support staff

Medical Tourism Considerations:

International patient services — dedicated coordinators, interpreters
Accommodation options — on-site or nearby housing for families
Visa assistance — help with travel documentation
Follow-up coordination — communication with home physicians
Package pricing — comprehensive packages including procedures and stay

Surgeon Selection Criteria:

Training and Credentials:

Board certification/qualification in cardiac surgery
Fellowship training in specialised cardiac surgery
Transplant fellowship — for transplant surgeons
Academic appointments — involvement in teaching and research
Special expertise — in specific procedure (LVAD, transplant, PTE, pericardiectomy)

Experience:

Years in practice — established surgeons with 10+ years experience
Procedure volume — surgeons performing >50 complex procedures annually
Special expertise — experience with complex cases, redo surgery
Transplant experience — number of transplants performed

Outcomes and Reputation:

Personal outcomes data — low mortality and complication rates
Patient reviews — satisfaction scores
Peer recognition — respected by other cardiac surgeons and cardiologists
Research contributions — publications, conference presentations

Communication Style:

Willingness to answer questions — approachable, thorough explanations
Shared decision-making — involves patient and family in treatment decisions
Second opinion openness — comfortable with patients seeking other opinions
Language — fluent in patient’s language or interpreter available

Practical Considerations:

Hospital affiliation — operates at reputable centre
Availability — reasonable wait time for elective surgery
Insurance participation — accepts patient’s insurance (if applicable)
Location — accessibility for frequent follow-up (especially for transplant/LVAD)

Red Flags to Avoid:

Low-volume surgeons or hospitals for complex procedures
Limited experience with specific patient’s anatomy/comorbidities
Poor communication or unwillingness to discuss outcomes
Marketing-focused rather than outcome-focused approach
Limited ICU or postoperative care capabilities
No transplant centre designation (for transplant/LVAD)

How to Evaluate:

Request outcome data (mortality, complication rates)
Ask about specific experience with cases like yours
Research online reviews and professional reputation
Consult with primary cardiologist for recommendations
Consider in-person consultation before committing
Transplant: review transplant centre outcomes in national registries
PTE: specifically seek centres with established PTE programmes

34. Questions to Ask Your Heart Specialist

Patients should ask these questions before undergoing procedures in this category:

About the Procedure:

Which specific procedure are you recommending for me, and why?
What alternative treatments are available?
What approach will you use — traditional, minimally invasive, or robotic? Why?
How many of this specific procedure have you performed?
What are the success rates for this procedure in your practice?
What are the potential benefits for my specific condition?

About Risks and Outcomes: 7. What are the specific risks for me based on my health profile? 8. What is your personal mortality and complication rate for this procedure? 9. What should I expect for quality of life after surgery? 10. Will this procedure extend my life expectancy? 11. What happens if the procedure doesn’t work as expected?

About Recovery: 12. How long will I be in the hospital? 13. What will my recovery be like at home? 14. When can I return to work? To driving? 15. Will I need cardiac rehabilitation? 16. What limitations will I have long-term? 17. LVAD: What are driving restrictions? How do I manage daily activities with the device? 18. Transplant: What are the long-term effects of immunosuppression?

About the Hospital and Team: 19. How many of this procedure does this hospital perform annually? 20. What is the hospital’s mortality rate for this procedure? 21. Who will be on my care team? 22. How will my pain be managed after surgery? 23. What happens if complications occur? 24. Transplant: What is your transplant centre’s survival rate compared to national averages? 25. PTE: How many PTE procedures does your centre perform annually?

About Medical Tourism (if applicable): 26. What accreditations does the hospital hold? 27. How will my follow-up care be coordinated after I return home? 28. What happens if I have complications after returning home? 29. What language services are available? 30. What are the total costs, and what do they include? 31. Transplant: How long must I stay near the transplant centre after surgery?

About Lifestyle and Medications: 32. What medications will I need to take long-term? 33. What lifestyle changes will be required? 34. Can I still travel? Exercise? 35. What dietary restrictions will I have? 36. LVAD: How often will I need INR checks? What if I live far from a lab? 37. Transplant: What are the risks and side effects of immunosuppressants?

Practical Questions: 38. How long is the waiting list for this surgery? 39. What do I need to do to prepare? 40. What should I bring to the hospital? 41. Who can I contact with questions after hours? 42. Transplant: What is the expected wait time for a donor heart? 43. LVAD: Who will be my primary caregivers for device management?

Long-Term Questions: 44. Will I need repeat procedures in the future? 45. What is the expected lifespan of the treatment (device, graft, transplant)? 46. LVAD: Will I be considered for transplant in the future? 47. Transplant: What happens if the donor heart fails?

Take notes during appointments, bring a family member or friend, and don’t hesitate to ask for clarification. A good surgeon welcomes informed questions and takes time to ensure patients understand.

35. Frequently Asked Questions

Q: How long do these procedures typically take? A: Procedure duration varies considerably. Pericardial window takes 1-2 hours. Pericardiectomy and cardiac tumour resection typically take 3-5 hours. LVAD implantation and surgical ventricular restoration usually take 4-6 hours. PTE is the longest, taking 6-10 hours due to the meticulous dissection required. Heart transplantation takes 4-8 hours depending on complexity. Family should expect the entire process (anesthesia, surgery, ICU stabilisation) to take 2-4 hours longer than the surgical time.

Q: Will I be on a heart-lung machine during surgery? A: It depends on the procedure. Pericardial window can often be done without the heart-lung machine. Cardiac tumour resection, LVAD implantation, SVR, and heart transplant all require cardiopulmonary bypass (heart-lung machine). PTE requires not only bypass but also deep hypothermia (cooling to 18-20°C) with periods of circulatory arrest (completely stopped circulation). Pericardiectomy may or may not require bypass depending on the extent of adhesions.

Q: How painful is the recovery? A: Most patients describe the pain as manageable with medications. The sternum (chest bone) is the most uncomfortable area, especially when coughing or moving. Pain typically improves significantly after the first week and is well-controlled with oral medications by discharge time (4-7 days for most procedures). Transplant and LVAD patients have longer hospitalisations and may require IV pain medications for longer periods. Leg incisions (if vein harvesting) can also be uncomfortable but improve steadily.

Q: When can I return to normal activities? A: This varies by procedure. After pericardial window, most return to normal activities in 4-6 weeks. After pericardiectomy or cardiac tumour resection, expect 6-8 weeks for basic recovery, 3-4 months for full recovery. LVAD and transplant patients require 3-6 months for full recovery but can gradually increase activities during that time. PTE has the longest recovery, often 6-12 months for complete pulmonary recovery. Driving is usually permitted at 4-6 weeks when sternum healed and off narcotics. Heavy lifting restricted until sternum fully healed (3 months).

Q: Will I need to take blood thinners? A: It depends on the procedure. Pericardiectomy and cardiac tumour resection patients typically don’t require long-term anticoagulation unless other indications exist (atrial fibrillation). LVAD patients require warfarin (Coumadin) lifelong to prevent device clotting, with INR monitoring typically ranging from every week to monthly. Heart transplant patients generally don’t require warfarin but take aspirin and other medications. PTE patients often continue anticoagulation for pulmonary hypertension. SVR patients typically take aspirin lifelong.

Q: What is the success rate for heart transplantation? A: Modern heart transplantation has excellent outcomes. One-year survival is 85-90%, five-year survival is 70-75%, and ten-year survival is 50-60%. These rates have improved significantly with modern immunosuppression and care. Success depends on recipient selection, donor quality, surgical expertise, and post-transplant care adherence. Most recipients return to near-normal quality of life.

Q: Can an LVAD be a permanent treatment? A: Yes, LVADs are used as “destination therapy” (permanent treatment) for patients not eligible for transplant due to age, comorbidities, or other factors. Modern continuous-flow LVADs can last 2-5 years, though some function longer. If the device fails, pump exchange (replacement) is possible. Some destination therapy patients eventually become eligible for transplant. LVADs significantly improve survival and quality of life compared to medical therapy alone for end-stage heart failure.

Q: What happens if pericarditis comes back after pericardiectomy? A: Recurrence of constrictive pericarditis after complete pericardiectomy occurs in 5-10% of cases. Options include repeat pericardiectomy (higher risk due to adhesions), medical management with diuretics, or creation of a pericardial window for fluid drainage. The best approach depends on individual anatomy, symptoms, and surgical risk. Complete pericardiectomy during initial surgery reduces recurrence risk.

Q: How long is the wait for a heart transplant? A: Wait time varies considerably by region, blood type, and urgency status. In most countries, median wait time is 6 months to 1 year, but can range from days to several years. Status 1A (most urgent) patients typically receive organs within days to weeks. Less urgent patients may wait 1-2 years. Blood type O candidates typically wait longer. Geographic location and donor availability also affect wait times. Patients must stay within 2-4 hours travel distance of transplant centre while waiting.

Q: Are there alternatives to PTE for CTEPH? A: For patients with CTEPH who are not surgical candidates (distal disease, too high risk), medical therapy with pulmonary hypertension medications (riociguat, other vasodilators) is the primary option. These medications don’t remove the clot but can improve symptoms and pulmonary pressures. Balloon pulmonary angioplasty (BPA) is an emerging catheter-based procedure for some patients with distal disease not amenable to surgery. However, PTE remains the only potentially curative treatment and has the best outcomes for suitable candidates.

Q: Will I need a pacemaker after these procedures? A: Pacemaker implantation is sometimes required after cardiac surgery but not routine. Pericardiectomy and cardiac tumour resection rarely require pacemakers unless there was pre-existing conduction disease or accidental injury to the heart’s electrical system (rare). SVR patients sometimes require pacemakers for ventricular arrhythmias. Heart transplant patients almost always have temporary pacing wires postoperatively, and a small percentage (<10%) require permanent pacemakers for slow heart rhythms. LVAD patients rarely need pacemakers specifically for the device but may have pre-existing indications.

36. Patient Stories and Treatment Experiences

Note: The following stories are representative of typical patient experiences with these procedures, with names and details modified for privacy.

Maria, 52, Colombia — Pericardiectomy

“I had been getting progressively more swollen for over a year. My abdomen was distended, my legs were huge, and I couldn’t breathe lying flat. After multiple hospitalisations for drainage, I was finally diagnosed with constrictive pericarditis. My local hospital said I needed surgery but wasn’t comfortable doing it. We found a centre in India specialising in pericardial surgery. The surgery took 4 hours, and I spent 6 days in the hospital. Within two weeks, I noticed dramatic improvement — I could breathe better, my swelling was decreasing. Now, two years later, I’m back to normal activities, taking no diuretics, and feel completely cured. My only regret is not pursuing the diagnosis earlier.”

Robert, 67, United Kingdom — LVAD Destination Therapy

“At 62, I was told I had end-stage heart failure and wasn’t eligible for transplant due to my age and kidney function. My only option was an LVAD as destination therapy. It was a difficult decision — living with a device, no transplant, uncertain future. But I wanted more time with my grandchildren. The surgery was long (7 hours) and the recovery tough (3 weeks in hospital). Learning to manage the device was overwhelming at first, but my wife was trained as my caregiver. Now, five years later, I’m still going strong. My original LVAD was exchanged after three years, and I’m on my second device. I can’t swim or play contact sports, but I walk daily, enjoy my family, and have had quality time I wouldn’t have had otherwise. It’s not a cure, but it’s given me life.”

Ahmed, 48, UAE — Heart Transplant

“I was only 42 when a viral infection destroyed my heart. Within months, I was in end-stage heart failure, unable to walk more than a few steps, on continuous IV medications. I was listed for transplant and waited 8 months — the hardest 8 months of my life, wondering if a donor would come in time. Finally, I got the call at 3 AM. The surgery took 6 hours. When I woke up, I could feel the difference immediately — my new heart was strong. The first year was challenging with rejection biopsies, medication adjustments, infections. But now, six years post-transplant, I’m back at work, traveling, exercising, and living a full life. I take 20 medications daily and will always need them, but it’s a small price for the gift of life. My donor’s family gave me the ultimate gift, and I honour them every day by living fully.”

Priya, 58, India — Cardiac Tumour Resection

“I had been having strange symptoms — episodes of passing out, feeling like my heart was racing, sometimes stroke-like symptoms that would resolve quickly. After many tests, they found a large tumour in my left atrium — an atrial myxoma. I was terrified it would break off and cause a major stroke. Surgery was scheduled urgently. The tumour was the size of a golf ball, attached to the atrial septum. They removed it completely and repaired the septum with a patch. I spent five days in the hospital and was back to normal in six weeks. Now, five years later, I’m completely healthy with no recurrence. The surgery saved me from a potentially catastrophic stroke.”

James, 62, Australia — PTE for CTEPH

“I had multiple blood clots in my lungs (pulmonary embolisms) over several years. Gradually, I became more and more short of breath. I was diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) — the old clots had turned into scar tissue blocking my pulmonary arteries. Medications weren’t helping. My doctors said there was a surgery available but only a few centres worldwide performed it. We travelled to a specialist centre in another country. The surgery was massive — 10 hours, with my body cooled to 18°C and my circulation completely stopped for periods while they meticulously scraped the scar tissue out of my pulmonary arteries. The recovery was slow — I was in the ICU for five days, hospital for three weeks. But gradually, my breathing improved. Now, two years later, my pulmonary pressures are normal, I’m walking 5km daily, and have returned to work. The surgery was literally life-saving.”

Sophie, 71, France — Surgical Ventricular Restoration

“I had a massive heart attack at 65 that left a large aneurysm in my left ventricle. Despite medications, my heart failure progressively worsened. I couldn’t walk across a room without stopping to breathe. My cardiologist discussed options and suggested SVR along with bypass surgery. They would remove the aneurysm and reconstruct my ventricle. The surgery took 6 hours (they also did three bypasses). I was in the hospital for 10 days. Recovery was slow — I felt worse before I felt better as my heart adjusted. But by three months, I noticed improvement. Now, six years post-op, my heart function is significantly improved, I have minimal symptoms, and I’m enjoying life with my grandchildren. It gave me a second chance.”

Patients considering or undergoing procedures in this category may benefit from understanding related cardiac procedures:

Coronary Artery Bypass Grafting (CABG) — SVR is almost always combined with CABG to address both ventricular aneurysm and underlying coronary artery disease. CABG may also be performed concomitantly with other procedures in this category.
Mitral Valve Procedures — Patients with advanced heart failure or after heart attacks may develop mitral regurgitation (leaky valve). Mitral valve repair or replacement may be combined with SVR, LVAD, or performed separately.
Aortic Valve Procedures — Some patients undergoing complex cardiac surgery may also have aortic valve disease. Combined procedures (valve replacement + other surgery) are common.
Minimally Invasive Cardiac LIS — Some pericardial procedures and certain cardiac tumour resections may be performed through smaller incisions using minimally invasive or thoracoscopic approaches.
Hybrid Cardiac Procedures — Combined approaches using both surgical and catheter-based techniques, increasingly used for complex cases involving multiple problems.

Patients with conditions requiring procedures in this category should also explore information about:

Heart Failure Treatments — Comprehensive information about managing heart failure, including medical therapies and device options
Pericardial Disease — Information about pericarditis and pericardial effusions
Pulmonary Hypertension — For CTEPH patients, understanding pulmonary hypertension is helpful

The optimal treatment strategy is determined by the heart team based on individual anatomy, symptoms, and overall health. Many patients benefit from a combination of approaches over their lifetime. For patients travelling internationally for care, understanding all available options helps in selecting the most appropriate treatment destination and centre.

38. Latest Research and Medical Advances

Techniques and outcomes for these complex procedures continue to evolve with ongoing research and technological advances:

Pericardiectomy Advances:

Improved imaging techniques — cardiac MRI better identifies constrictive pericarditis vs restrictive cardiomyopathy
Thoracoscopic and robotic approaches — minimally invasive pericardiectomy for select patients
Better phrenic nerve identification — intraoperative nerve monitoring reduces injury risk
Enhanced postoperative care — standardised protocols reduce complications

LVAD Technology:

Third-generation devices — HeartMate 3 with magnetically levitated rotor (lower thrombosis risk)
Smaller, more efficient devices — less invasive implantation
Fully implantable devices — research on devices without external driveline (reducing infection risk)
Remote monitoring — device data transmission to centres for early problem detection
Bridge to recovery — some patients recover enough heart function to have device removed

Heart Transplantation Advances:

Immunosuppression advances — newer medications with fewer side effects
Desensitisation protocols — allowing transplant across previously incompatible blood types or with sensitised recipients
Ex vivo perfusion — keeping donor hearts functioning outside body (“heart in a box”) to expand donor pool
Mechanical circulatory support as bridge — LVAD and ECMO support keeping patients alive until transplant
Xenotransplantation research — pig-to-human transplantation (early clinical trials)
Artificial heart development — total artificial heart for bridge to transplant or destination therapy

PTE Advances:

Better patient selection — improved imaging identifies surgical candidates
Refined surgical technique — true endarterectomy with more complete removal
Deep hypothermia management — improved circulatory arrest protocols
Hybrid approaches — combined PTE and balloon pulmonary angioplasty for distal disease
International centre collaboration — centralising expertise for this rare procedure

Cardiac Tumour Management:

Better imaging — 3D echocardiography, cardiac MRI for precise tumour characterisation
Minimally invasive resection — smaller incisions for selected tumours
Robotic-assisted approaches — enhanced visualization and precision
Genetic analysis — identifying tumour types for personalised treatment

Surgical Ventricular Restoration:

Refined patient selection — better identification of who benefits
Less invasive approaches — epicardial patch placement (LESS procedure)
Combined procedures — optimised concurrent CABG and valve repair
Stem cell therapy — investigational adjunct to enhance recovery

Perioperative Care Advances:

Enhanced recovery after surgery (ERAS) protocols — standardised pathways reducing complications
Blood conservation strategies — minimising transfusions
Specialised ICU care — dedicated cardiac intensivists improving outcomes
Telemedicine follow-up — virtual visits for routine postoperative care
Remote monitoring — wearable devices transmitting vital signs and device data

Medical Tourism Developments:

Increasing international accreditation — JCI, ISO certifications
Standardised outcomes reporting — transparent data for patients
Improved international patient services — dedicated coordinators, interpreters
Better coordination for follow-up care — communication with home physicians

Patients should discuss emerging techniques with their surgeons, while recognising that proven approaches remain the standard of care. Participation in clinical trials may be an option for some patients at academic centres.

39. Medical Review, Guidelines and References

This content aligns with current cardiology and cardiac surgery guidelines and is based on reputable medical sources:

Professional Society Guidelines:

American College of Cardiology/American Heart Association (ACC/AHA) — Guidelines for the Management of Heart Failure, Guidelines for the Diagnosis and Treatment of Pericardial Diseases
European Society of Cardiology (ESC) — Guidelines for the diagnosis and treatment of acute and chronic heart failure, ESC Guidelines on pericardial diseases
International Society for Heart and Lung Transplantation (ISHLT) — Guidelines for the care of heart transplant recipients, guidelines for mechanical circulatory support
Society of Thoracic Surgeons (STS) — Adult Cardiac Surgery Database and clinical practice guidelines
American Association for Thoracic Surgery (AATS) — Consensus statements on complex cardiac surgery

Authoritative Sources:

National Institute for Health and Care Excellence (NICE) — Guidelines on chronic heart failure, interventional procedures overview
UpToDate — Comprehensive medical information on cardiac surgery procedures
Cleveland Clinic, Mayo Clinic, Johns Hopkins — Clinical practice guidelines and patient education materials
American Heart Association — Patient education on cardiac surgery and heart failure

Standard Textbooks and References:

Sabiston and Spencer Surgery of the Chest — Comprehensive cardiac surgery textbook
Cohn’s Cardiac Surgery in the Adult — Standard reference for adult cardiac surgery
Braunwald’s Heart Disease — Comprehensive cardiology textbook
Mechanical Circulatory Support — Specialist textbook on LVAD and assist devices

Patient Resources:

American Heart Association (heart.org)
British Heart Foundation (bhf.org.uk)
Heart Failure Society of America
Transplant Living (transplantliving.org)
LVAD patient support groups

Key Clinical Trial References:

REMATCH Trial — LVAD vs medical therapy for destination therapy
HeartMate II and HeartMate III Trials — Modern continuous-flow LVAD outcomes
BASIC Trial — Pericardiectomy vs medical management
International PTE Registry — Outcomes for pulmonary thromboendarterectomy
TRANSIT Study — SVR outcomes
UNOS Database — Transplant outcomes data

Outcomes Data:

Society of Thoracic Surgeons National Database
EuroSCORE risk calculation models
ISHLT Transplant Registry
INTERMACS Registry (for mechanical circulatory support)
Institutional outcome reports from major cardiac centres

Medical knowledge and guidelines evolve. This information is current as of 2024. Patients should discuss the latest evidence and approaches with their cardiac team. Decisions about individual care should be made with qualified healthcare providers considering all patient-specific factors.

40. Book a Consultation / Get a Second Opinion

Taking the step toward complex cardiac surgery is significant, and ensuring you have the best information and care team is essential. Whether you’re exploring options, preparing for surgery, or seeking confirmation of a recommended treatment plan, consultations with experienced cardiac specialists provide clarity and confidence.

When to Seek a Consultation:

You’ve been diagnosed with a complex cardiac condition requiring specialised surgery
Pericardiectomy, cardiac tumour resection, LVAD, transplant, PTE, or SVR has been recommended
You’re considering medical tourism and want to evaluate international hospitals and surgeons
You’ve been told you’re not a candidate for transplant but want to explore options
You’re considering LVAD as destination therapy vs bridge to transplant
You have questions about your specific case and options
You’ve had previous cardiac surgery with recurrent symptoms
You want to confirm a diagnosis or treatment plan

What to Expect During a Consultation:

A comprehensive cardiac consultation typically includes:

Detailed review of your medical history, symptoms, and previous cardiac tests
Physical examination focused on cardiovascular system
Review of all imaging (echocardiograms, CT scans, MRI, angiograms)
Discussion of treatment options tailored to your anatomy and health
Clear explanation of benefits, risks, and alternatives
Opportunity to ask all your questions
Discussion of logistics, costs, and planning (especially for medical tourists)
Transplant candidates: comprehensive psychosocial evaluation

Getting a Second Opinion:

Second opinions are encouraged and often recommended for major cardiac procedures, especially in this category. They can:

Confirm the initial recommendation
Present alternative treatment options
Provide different perspectives on complex cases
Increase confidence in the treatment plan
Connect you with surgeons experienced in your specific situation
Transplant/LVAD: explore eligibility at different centres

How to Arrange a Consultation:

For patients considering treatment in India, Turkey, Thailand, Singapore, or other medical tourism destinations:

Book Your Free Consultation Today

Our international patient coordinators will:

Connect you with experienced cardiac surgeons and cardiologists
Facilitate review of your medical records and test results
Arrange telemedicine or in-person consultations
Provide detailed cost estimates and treatment plans
Assist with travel logistics, accommodation, and appointments
Coordinate your care from initial consultation through recovery and follow-up
Transplant candidates: coordinate evaluation and listing process

For general inquiries and local options:

Contact Us to discuss your needs and learn about hospitals and cardiac specialists in your region or our international partner network.

Preparing for Your Consultation:

To make the most of your consultation:

Gather all previous cardiac test results (angiograms, echocardiograms, CT scans, MRIs, stress tests)
Bring a list of all current medications with dosages
Prepare a timeline of your symptoms and treatments
Write down your questions in advance
Consider bringing a family member or friend for support and note-taking
Transplant/LVAD: prepare financial information, identify potential caregivers
Be prepared to discuss your lifestyle, occupation, and what matters most to you
Transplant: be prepared to discuss social support system, living situation

Special Considerations by Procedure:

Transplant Consultations:

Comprehensive evaluation including blood tests, imaging, psychosocial assessment
Discussion of waiting times, donor process
Financial counselling (immunosuppressant costs)
Caregiver requirements (must identify support system)

LVAD Consultations:

Device selection discussion (different LVAD options)
Caregiver training requirements
Lifestyle modifications (no driving, swimming limitations)
Long-term commitment to device management

PTE Consultations:

Review of CT pulmonary angiography and conventional angiography
Assessment of surgical accessibility of thrombi
Discussion of alternative medical therapies

Don’t delay in seeking expert cardiac care. These complex conditions often progress, and early intervention leads to better outcomes. Whether you’re just beginning to explore options or ready to schedule surgery, expert guidance is essential for optimal results.

Connect with top cardiac specialists worldwide. These procedures require expertise available only at specialised centres. Your heart health deserves the best care available, wherever you choose to receive it.

For international patients seeking complex cardiac surgery, we offer streamlined access to world-renowned centres with demonstrated expertise in pericardiectomy, cardiac tumour resection, LVAD implantation, heart transplantation, pulmonary thromboendarterectomy, and surgical ventricular restoration.

Other Procedures

1. Procedure Overview

2. Key Facts at a Glance

3. Anatomy and How the Heart Condition Develops

4. Conditions Treated

5. Symptoms and Warning Signs

6. When Is This Procedure Recommended?

7. Who Is a Suitable Candidate?

8. Who May Not Be Suitable?

9. Types and Techniques of the Procedure

10. Traditional, Minimally Invasive and Advanced Approaches

11. Procedure vs Alternative Treatments

12. Diagnosis and Pre-Procedure Evaluation

13. Tests Required Before the Procedure

14. How to Prepare for the Procedure

15. Procedure: Step-by-Step

16. Anaesthesia and Procedure Duration

17. Technology, Devices and Equipment Used

18. Benefits of the Procedure

19. Success Rate and Expected Outcomes

20. Risks and Possible Complications

21. Hospital Stay and Immediate Aftercare

22. Recovery Timeline

23. Pain Management and Wound Care

24. Medications After the Procedure

25. Diet, Exercise and Lifestyle Guidelines

26. Cardiac Rehabilitation

27. Follow-Up Tests and Long-Term Monitoring

28. Warning Signs After the Procedure

29. Long-Term Results and Procedure Durability

30. Repeat Procedure and Reintervention

31. Cost of the Procedure

32. Factors Affecting Procedure Cost

33. Choosing the Best Hospital and Specialist

34. Questions to Ask Your Heart Specialist

35. Frequently Asked Questions

36. Patient Stories and Treatment Experiences

37. Related Cardiac Procedures

38. Latest Research and Medical Advances

39. Medical Review, Guidelines and References

40. Book a Consultation / Get a Second Opinion

Ready to take the next step for your heart?